



**Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003083
Article Type:	Research
Date Submitted by the Author:	18-Apr-2013
Complete List of Authors:	Thomas, Ranjeny; The University of Queensland, White, Douglas Pahau, Helen Duggan, Emily Paul, Sanjoy
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Epidemiology
Keywords:	RHEUMATOLOGY, EPIDEMIOLOGY, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Trajectory of intensive treat-to-target disease modifying drug regimen in an**  
5  
6 **observational study of an early rheumatoid arthritis cohort**  
7

8 Douglas White<sup>1</sup>, Helen Pahau<sup>1</sup>, Emily Duggan<sup>1</sup>, Sanjoy Paul\*<sup>2</sup> and Ranjeny Thomas\*<sup>1</sup>  
9  
10

11  
12  
13 <sup>1</sup> - Diamantina Institute, University of Queensland, Princess Alexandra Hospital,  
14 Ipswich Road, Woolloongabba, Queensland, Australia  
15

16  
17 <sup>2</sup> - Queensland Clinical Trials and Biostatistics Centre, School of Population Health,  
18 University of Queensland, Translational Research Institute, Princess Alexandra  
19 Hospital, Queensland, Australia  
20  
21

22  
23  
24 \* These authors contributed equally to the work  
25

26 Corresponding author: Ranjeny Thomas,  
27

28 email: ranjeny.thomas@uq.edu.au  
29

30 Telephone: +61734436960  
31

32 Fax: +61734436966  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

Objectives: Studies of early rheumatoid arthritis (RA) cohorts have analysed treatment response and prognostic factors at fixed time points. However, in treat-to-target protocols, therapeutic decision-making is dynamic, and responsive to disease activity over time. To determine when a minimal residual disease response target should be expected, our primary objective was to identify the time-dependent therapeutic response to combination disease modifying anti-rheumatic drugs (DMARDs) for 12 months. Our secondary objective determined factors affecting this response trajectory. Design: Observational cohort. Setting: Treat-to-target early RA clinic in Australian tertiary referral hospital. Participants: We enrolled consecutive patients attending an early arthritis clinic with symptom duration less than 12 months, who were diagnosed with RA for the first time between 2004 and 2008. One hundred and one met these eligibility criteria and data were available at baseline through 12 months. Interventions: Intensive DMARDs according to a treat-to-target protocol. Primary and secondary outcome measures: We measured disease activity scores (DAS) at each visit, then analysed therapeutic response and associated factors in a time-dependent fashion over 12 months. Results: The median DAS4vESR of 4.46 at baseline decreased 12 weeks later by 24%, while the proportion with  $DAS4v \leq 2.6$  increased ( $p < 0.01$ ). DAS4v continued to decrease over 52 weeks. DAS4v reduction of at least -0.45 at 4 weeks was predictive of DAS4v at 28 and 52 weeks. Female gender and an interaction between baseline weight and CRP negatively impacted DAS4v reduction over 4 and 52 weeks. Time-varying effects of blood pressure, neutrophils, ESR and CRP also significantly influenced DAS4v over 52 weeks. Conclusions: Time-dependent data suggest that the largest reduction of DAS4v to combination DMARDs occurs in the first month of therapy, and

1  
2  
3  
4 this predicts subsequent response. The data suggest the need for a controlled trial of  
5  
6 treatment change within 1 month, in combination DMARD non-responding patients.  
7

## 8 **Article Summary**

### 9 **Article focus**

- 10 • Best-practice early RA treatment aims to achieve a target response. In clinic  
11 settings of many countries, first-line therapies are DMARDs, including  
12 combination DMARDs  
13
- 14 • We followed an observational cohort for 12 months in a treat-to-target early RA  
15 clinic to identify the time-dependent therapeutic response to combination  
16 DMARDs for 12 months and factors affecting this response trajectory  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Key messages**

- 27 • After initiation of combination DMARDs, the largest reduction in disease  
28 activity score occurred in the first month, and its magnitude predicted  
29 subsequent response  
30  
31
- 32 • Disease activity score over 12 months was influenced by female gender and  
33 current smoking, and an interactive effect of weight and either CRP or ESR  
34  
35
- 36 • The data suggest a need for a controlled trial of treatment change within 1  
37 month, in combination DMARD non-responding patients.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Strengths and Limitations**

#### 47 **Strengths**

- 48 • Monthly observation allowed precise determination of time-dependent  
49 therapeutic response and demonstrated an unexpectedly rapid response to  
50 combination DMARDs  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Standardised combination DMARD treat-to-target protocol
- Real-life clinical setting with dynamic therapeutic decision making

### Limitations

- Observational cohort study limits conclusions that can be drawn regarding causality, without further testing in a randomised controlled trial
- Relatively small cohort derived from a single centre, with treatment regimen determined within Australian prescribing context, limits generalisability.
- Number of participants limited by lack of baseline or 12 month follow-up data and may have introduced selection bias
- Due to incomplete radiographic data, factors associated with radiographic outcomes could not be determined

**BACKGROUND:**

Intervention with early combination disease modifying anti-rheumatic drug (DMARD) therapy favourably influences progression of rheumatoid arthritis (RA) independent of treatment in later years, suggesting that there is a “window of opportunity” in which the disease process can be altered [1, 2]. Moreover, a good response at 6 months to tight disease control using methotrexate predicted outcome after 5 years of treatment in participants in the CAMERA study [3]. The severity of disease varies in RA patients. In those with aggressive disease, damage to articular structures occurs early in the disease process: erosions were detected in 12.8% of patients after a median of 8 weeks in one study [4]. Thus, early evidence and determinants of treatment response to a given regimen are critical, in order to channel patients at greatest risk of poor outcome to more intensive induction regimens or more expensive biologic therapies within that window.

Studies of prognostic factors by statistical modelling have analysed disease progression outcomes including erosions, disease activity score (DAS28) and disability index as measured by Health Assessment Questionnaire (HAQ) at fixed time points – usually 6 or 12 months, with the earliest being 3 months – to determine treatment response and associated factors influencing this. Factors associated with poor radiological outcome include smoking, rheumatoid factor (RF) positivity, the presence of anti-citrullinated peptide autoantibodies (ACPA), HLA-DR genotype, low socioeconomic status and bone oedema on magnetic resonance imaging [5-9]. On the other hand, poor outcome measured by HAQ was associated with high baseline disease activity or HAQ, including RF, DAS28 score, tender and swollen joint counts, ESR and CRP [10, 11]. However, in treat-to-target protocols, such as was used in the TICORA trial and which occur in real-

1  
2  
3  
4 life clinic settings, decision-making about dose and drugs is a dynamic process,  
5  
6 responsive to the patient's disease activity over time [12]. In many early arthritis  
7  
8 protocols, including the current study, patients are treated and monitored intensively  
9  
10 during the first 3-6 months, followed by a reduced visit frequency. Longitudinal  
11  
12 analysis of all available data, while modelling the trajectories and drawing inferences on  
13  
14 the significance of various risk factors, provides higher power and better insight into the  
15  
16 dynamic process.  
17  
18  
19  
20

### 21 22 **AIMS:**

23  
24 In the current study, our primary objective was to identify the time-dependent  
25  
26 therapeutic response in an observational study of combination DMARDs for 12 months  
27  
28 in order to determine when a minimal residual disease response target should be  
29  
30 expected. Our secondary objective was to determine factors affecting this response  
31  
32 trajectory. We therefore gathered disease activity data at each treatment visit then  
33  
34 analyzed the disease activity response in a time-dependent fashion. We then determined  
35  
36 factors which influenced this time-dependent response to an intensive DMARD  
37  
38 regimen.  
39  
40  
41  
42  
43

### 44 45 **METHODS:**

46  
47 We enrolled consecutive patients attending a tertiary referral early arthritis clinic with  
48  
49 symptom duration less than 12 months, who were diagnosed with RA for the first time  
50  
51 between 2004 and 2008. Patients were selected for inclusion in the current study if data  
52  
53 were available at baseline through 12 months. One hundred and one patients met these  
54  
55 eligibility criteria; however 107 patients who met all other criteria were excluded as  
56  
57  
58  
59  
60

1  
2  
3  
4 data were unavailable at either baseline or 12 months. All study participants met the  
5  
6 American College of Rheumatology 1987 revised criteria for the classification of RA  
7  
8 [13]. Ethical approval for the study was obtained from the Princess Alexandra Hospital  
9  
10 Research Ethics Committee.  
11

12  
13  
14 Referrals from local general practitioners were triaged within 1 week, and patients were  
15  
16 generally diagnosed within the next 4 weeks. Since full clinical and laboratory  
17  
18 evaluation was available at the first visit to the early arthritis clinic, patients received  
19  
20 combination methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ)  
21  
22 [14], unless contraindicated, immediately after diagnosis and confirmation of active  
23  
24 disease by the treating rheumatologist. Treatment was intensified according to a  
25  
26 response-driven step-up algorithm, as previously described [15], with remission as the  
27  
28 target [16, 17]. Briefly, criteria for dose escalation were either >2 swollen joints and  
29  
30 abnormal ESR or CRP, or at least 2 of the following 4 criteria: morning stiffness  
31  
32 >30mins, pain or fatigue visual analogue scale (VAS) >30mm, or >2 tender joints. The  
33  
34 following medications were prescribed at baseline: MTX 10mg/week, folic acid  
35  
36 5mg/week, SSZ 500mg daily increasing by 500mg at weekly intervals to 1000mg twice  
37  
38 daily, HCQ 200mg daily for one week then 400mg daily thereafter. Patients were seen  
39  
40 at 4-weekly intervals and the MTX dose was escalated according to treatment response  
41  
42 at a conservative rate by 5mg at each visit to a maximum of 25mg weekly. If disease  
43  
44 remained active on this combination, SSZ was stopped, MTX reduced to 10mg weekly  
45  
46 and leflunomide started at a dose of 20mg daily. MTX dose was titrated back to 25mg  
47  
48 weekly, and if this combination failed and the Australian Pharmaceutical Benefit  
49  
50 Scheme criteria were met, the patient commenced biologic therapy. Based on these  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 criteria, 10% of patients in this setting commenced biologics per year. In general, the  
5  
6 use of NSAIDs and oral corticosteroids was minimized, but intra-articular or oral  
7  
8 steroids could be administered at the discretion of the treating physician. Large joints  
9  
10 were injected with 40-80mg DepoMedrol and smaller joints with 1ml (5.7mg)  
11  
12 Celestone. Oral and intra-articular dosage of corticosteroids was recorded monthly.  
13

14  
15  
16  
17 Response to therapy was measured as follows: the 4 variable DAS28ESR (hereafter  
18  
19 referred to as DAS4v) was used as an index of inflammatory control [18], and the  
20  
21 mHAQ as an index of disability [19]. Each index was calculated at each visit: baseline,  
22  
23 and weeks 4, 8, 12, 16, 22, 28, 36, 44 and 52.  
24  
25  
26  
27

28 Demographic details were ascertained by questionnaire and included: age at  
29  
30 presentation, gender, smoking status and mHAQ. Patients completed VAS for pain,  
31  
32 fatigue and their global assessment of disease. The 28 tender and swollen joint counts,  
33  
34 height and weight were recorded by the clinical research nurse. Blood was collected at  
35  
36 baseline for the analysis of ESR, CRP, LFT, FBC, RF and ACPA.  
37  
38  
39  
40

41 Basic statistics were presented by number (%) or mean (SD) or median (IQR), as  
42  
43 appropriate. Five imputations for missing data on clinical, biochemical and score data  
44  
45 were performed using Bayesian Markov chain Monte Carlo multiple-imputation  
46  
47 technique. The patterns of missingness were random for all the study parameters. The  
48  
49 consistency in the distributions of the 5 imputed data was checked for all study  
50  
51 parameters. Given the skewed DAS and mHAQ scores, the medians and their 95%  
52  
53 confidence intervals (CI) are presented. The changes in these scores over the study  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 period are presented by median and 95% CI, and the significance levels (p values) are  
5  
6 based on the appropriate non-parametric test.  
7  
8  
9

10  
11 Generalized multivariate linear regression models with Gamma distribution and Identity  
12 link were used to identify the statistically significant ( $p \leq 0.10$ ) risk factors and their  
13 possible interaction effects on disease activity scores at week 4 of the study. The  
14 possible consistency in the effect sizes of the statistically significant risk factors (at  
15 week 4) were also assessed on the disease activity scores at week 12 of the study.  
16  
17 Combining the 10 longitudinal measurements obtained over one year of the study, the  
18 time varying effects of individual risk factors on the disease activity scores were  
19 explored using generalized estimating equation (GEE) regression approach with  
20 Gamma distribution and identity link function under the assumption of 'unstructured'  
21 correlation structure.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**RESULTS:****Time-dependent therapeutic response to combination DMARDs for 12 months**

One hundred and one patients were included in the study. The baseline characteristics of the patients are shown in Table 1. All except 4 patients took at least two and up to three of the following DMARDs in combination during the 12 months study: Methotrexate, Sulfasalazine, Hydroxychloroquine and Leflunomide. These 4 patients took Methotrexate monotherapy.

The median disease activity score at baseline was 4.46 for DAS4v (Table 2). Four of the 12 patients with baseline DAS  $\leq 2.6$  were taking steroids prior to referral. There was a highly significant ( $p < 0.001$ ) DAS reduction of 24% at 28 weeks (Table 2). We also observed a significant increase in the proportion of patients with minimal residual, (DAS28 scores  $\leq 2.6$ ) and low disease (DAS28 scores  $\leq 3.2$ ) over the treatment period ( $p < 0.01$ ) (Table 2). Consistent with this, the patients' pain scores improved highly significantly by 31% and 56% at the end of 6-month and one-year of treatment respectively. The improvement in mHAQ from baseline to 6 months, but not between 6 and 12 months of treatment, was significant. The average annual change was 0.30 units (Table 2).

Analysis of the change in DAS4v over time showed a progressive reduction over 52 weeks, with the steepest drop between baseline and 4 weeks (Figure 1). The median (95% CI) of changes in DAS4v scores at 4, 28 and 52 weeks were -0.45 (-0.84, -0.07), -0.86 (-1.30, -0.41), and -1.35 (-1.67, -1.03) respectively ( $p < 0.01$  at week 52). The changing patterns of the distribution of DAS4v scores over time are evident from the

1  
2  
3  
4 density plots in Figure 2. Although a significant shift in the distribution of DAS4v at 4  
5 weeks from baseline is evident from the density plot, the distributions overlap at 4, 28  
6 and 52 weeks.  
7  
8  
9

10  
11  
12 Analysis of the individual components of the DAS scores over this period demonstrated  
13 that patient global score, swollen and tender joint counts all fell most steeply between  
14 baseline and 4 weeks (Figure 2). While this was not the case for the fall in either ESR or  
15 CRP, similar steep falls in fatigue score, morning stiffness and physician global scores  
16 occurred between baseline and 4 weeks. Thus most measures of disease activity fell  
17 most rapidly in the first 4 weeks after DMARD initiation. In contrast, ESR fell for 3  
18 months before reaching a plateau, while CRP fell progressively for 6 months.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Factors affecting the response trajectory in early RA patients treated with** 31 **combination DMARDs** 32 33

34  
35 To determine whether the fall in DAS4v at 4 weeks predicted the DAS score at 28 and  
36 52 weeks, we first calculated that the median level of change in DAS4v score at 4  
37 weeks was -0.45. This was clinically discriminatory: at 4 weeks, 52% had no change or  
38 an increase in DAS4v while 48% improved from baseline DAS4v. The number and  
39 proportion of patients receiving steroids is indicated in Table 3. While baseline steroids  
40 impacted the likelihood of improvement at 4 weeks, this was not statistically significant  
41 (69% of patients receiving steroids improved and 53% not receiving steroids improved;  
42 odds ratio for improvement with steroids 1.95,  $p=0.12$ ). Patients with reduction in  
43 DAS4v score at 4 weeks of at least -0.45 were three times more likely [OR (95% CI):  
44 3.10 (1.2, 8.0)] at 28 weeks and 17 times more likely [OR (95% CI): 17.14 (4.52,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 64.94)] at 52 weeks to maintain the same or reduced DAS4v score as achieved after 4  
5  
6 weeks of treatment. Univariate modelling of factors affecting outcome showed that  
7  
8 female sex, smoking status and increasing ALT at baseline negatively affected DAS4v  
9  
10 at 4 weeks, but these effects became less significant by 12 weeks (Table 4). An  
11  
12 interaction between baseline weight and CRP negatively affected DAS at both week 4  
13  
14 and 12. Patients taking steroid did not have a significantly different disease score, and  
15  
16 anti-CCP and RF titre did not impact 4 week DAS.  
17  
18  
19  
20

21  
22 Combining baseline characteristics and the longitudinal measurements obtained over  
23  
24 one year, we explored the time varying effects of individual risk factors on DAS4v in a  
25  
26 univariate model. DAS4v over 52 weeks was again influenced by female gender and  
27  
28 current smoking, and an interactive effect of weight and either CRP or ESR. Time  
29  
30 varying effects of systolic and diastolic blood pressure, neutrophil counts, ESR and  
31  
32 CRP also significantly influenced DAS4v observed over 52 weeks (Table 4). Over the  
33  
34 course of the study, DAS4v was increased by 0.66 in those patients taking steroids ( $p <$   
35  
36  $0.01$ ). These data are in keeping with the use of steroid in this study at the clinician's  
37  
38 discretion, to provide additional control for disease activity that was not controlled by  
39  
40 the DMARD protocol.  
41  
42  
43  
44  
45

46 We found that the relationship between mHAQ and DAS4v for the cohort was  
47  
48 significantly correlated at baseline, 4 weeks, 28 weeks and 52 weeks ( $p < 0.001$ ), with  
49  
50 this correlation becoming progressively tighter over time as DAS and mHAQ fell. Thus,  
51  
52 functional outcome after 1 year of early RA treatment is highly dependent on  
53  
54 achievement of low disease activity.  
55  
56  
57  
58  
59  
60

**DISCUSSION:**

Our study describes the response of a group of patients with early RA to intensive conventional DMARD therapy in a time-dependent fashion over the first year. Baseline characteristics were in line with previous cohorts of patients with early RA. However, our baseline DAS scores were relatively low, reflecting our rapid triage and clinical and laboratory assessment of early arthritis referrals. A key finding from the time-dependent analysis of response, is that the majority of disease activity measures fall most rapidly in the first 4 weeks after commencing intensive DMARD treatment. There was a subsequent slow and progressive reduction in DAS until week 52. Moreover, the fall in DAS4v at 4 weeks predicted the DAS score at 28 and 52 weeks. This observation suggests that for patients who fail to respond within 4 weeks to combination DMARD treatment, few gains are made by continuing to apply the same DMARD treat-to-target algorithm for 6-12 months. On the other hand, continued effort in applying a treat-to-target combination DMARD algorithm is likely to be effective over the ensuing months in patients who make a moderate response by week 4. Our data suggest that combination DMARDs act unexpectedly rapidly, as patients' use of steroids did not influence the reduction in DAS. In support of this conclusion regarding steroids, in a study of 61 patients with early RA treated according to a similar response-driven step-up combination DMARD algorithm, Proudman *et al* obtained an almost identical 6 month remission rate (DAS28<2.6 in 29%), despite infrequent use of corticosteroids [17].

1  
2  
3  
4 The current study has a number of limitations. Firstly, our interpretation that the  
5 magnitude of the fall in DAS4v after 1 month predicts 1 year outcome is limited by the  
6 observational study design. However, the question of whether outcome could be  
7 improved in patients with a minimal treatment response within 1 month could be tested  
8 in a randomised controlled trial comparing switch to biologic therapy with continued  
9 combination DMARDs. Secondly, this is a relatively small cohort derived from a single  
10 centre, with the treatment regimen determined within the Australian prescribing context.  
11 The number of participants was limited by lack of baseline or 12 month follow-up data  
12 and this may have introduced selection bias towards a more compliant group. While  
13 these factors may limit generalisability to other prescribing environments or clinical  
14 settings, the strengths of this study are that monthly observations allowed precise  
15 determination of time-dependent response and were able to demonstrate an  
16 unexpectedly rapid response to combination DMARDs. Furthermore, patients received  
17 a standardised combination DMARD treat-to-target protocol, reducing the confounding  
18 effect of treatment decisions based on individual clinician preference.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Finally the exploratory nature of the study in a relatively small sample could introduce  
41 false positive associations. By regression analysis, we identified female gender, current  
42 smoking, ALT and an interaction between weight and CRP as significant determinants  
43 of disease activity over 4 and 52 weeks. Females and current smokers were found in  
44 several studies, including those of early RA, to achieve lower reductions in disease  
45 activity or remission than men [20, 21]. The interaction between weight and  
46 inflammation in RA is intriguing and has been noted previously in insulin resistant  
47 states [22]. In patients with active RA, those with high BMI responded less well to  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 infliximab [23]. We also identified significant time-varying effects of blood pressure,  
5  
6 gender, age, weight and inflammatory markers on disease activity. The interaction  
7  
8 between disease activity and cardiovascular risk is well documented in RA, including  
9  
10 early RA, and traditional cardiovascular risk factors may also impact the activity of  
11  
12 inflammatory disease over time [15, 24-26]. However, it is unknown whether control of  
13  
14 cardiovascular risk factors can in turn impact inflammatory disease control.  
15  
16

17  
18  
19 In this study we were limited to analysis of disease and functional score, as radiographic  
20  
21 data were not sufficiently complete to allow measurement of structural damage.  
22  
23 However, this issue has been addressed by others, where biomarkers such as ACPA  
24  
25 antibodies, RF, CRP and cartilage oligomeric matrix protein can add power to  
26  
27 predictive models of bone erosion in early RA [27]. In contrast, we found no impact of  
28  
29 ACPA or RF on DAS. Our data confirm a strong relationship between disease activity  
30  
31 and functional score that appears to strengthen over time, a finding that is supported by  
32  
33 data from the BeST cohort [16]. We would anticipate that functional disability would be  
34  
35 minimized by early treatment with combination DMARDs as shown previously [28,  
36  
37 29].  
38  
39  
40  
41  
42  
43

44 Since they are traditionally thought to be slow acting, previous studies of DMARD  
45  
46 monotherapy in early RA have not analyzed time-dependent data from 4 weeks.  
47  
48 Although it remains possible that a similar response might be observed in some patients  
49  
50 starting DMARD monotherapy, we suggest this rapid response may be a unique feature  
51  
52 of intensive combination DMARD initiation in early RA. The risks and benefits of  
53  
54 intensive DMARD therapy (combinations allowing switching to achieve tight control)  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 versus monotherapy in early RA deserve further study, considering overall inconclusive  
5  
6 evidence to support combination DMARD therapy in RA [30]. The need to identify  
7  
8 patients with more aggressive disease prompted one group to undertake a trial of a  
9  
10 stratified treatment plan based on the likelihood of persistent arthritis, with the aim of  
11  
12 minimizing over- and under-treatment in early RA [31]. Our data suggest that very early  
13  
14 response to an intensive DMARD strategy that minimizes under-treatment predicts  
15  
16 response for the first year.  
17  
18  
19

20  
21 Data from the ERAN study show that patients with moderate disease activity at 1 year  
22  
23 are unlikely to achieve better control of their disease if the same protocol is continued,  
24  
25 and a good response at 6 months in the CAMERA study predicted outcome at 5 years  
26  
27 [3, 32]. Our data, collected in a cohort of early RA patients with relatively low baseline  
28  
29 DAS, likely reflect the trajectory of patients meeting criteria for RA early in disease,  
30  
31 and which would be captured in organized clinical settings using the recently-published  
32  
33 new classification criteria [33].  
34  
35  
36  
37  
38  
39

#### 40 **CONCLUSIONS :**

41  
42 With the availability of increasing numbers of treatment options, application of  
43  
44 strategies that identify early non-responders to intensive DMARD combinations, has  
45  
46 clear implications for treatment stratification within the window of opportunity. Our  
47  
48 time-dependent data suggest the need for a controlled trial of early treatment change in  
49  
50 patients who fail to respond to combination DMARDs in the first month of therapy.  
51  
52 Female gender, smoking, over-weight and abnormal LFT increase the risk of early poor  
53  
54 response.  
55  
56  
57  
58  
59  
60

## DATA SHARING, COMPETING INTERESTS AND FUNDING

Technical appendix, statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open access home for the dataset. The authors declare no competing interests in relation to this article. Supported by NHMRC grants 351439 and 569938. R.T. is supported by Arthritis Queensland and an ARC Future Fellowship.

## CONTRIBUTORSHIP

DW, SP, RT: Conception and design

DW, HP, ED: acquisition of data, analysis and interpretation of data

DW, SP, RT: Drafting the article or revising it critically for important intellectual content, and final approval before submission.

## REFERENCES

- 1 Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *The Lancet*. 1997; **350**:309-18.
- 2 Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet*. 1999; **353**:1568-73.
- 3 Bakker MF, Jacobs JWG, Welsing PMJ, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. *Ann Rheum Dis*. 2011.
- 4 Machold KP, Stamm TA, Eberl GJM, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. *The Journal of Rheumatology*. 2002; **29**:2278-87.
- 5 Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. *Rheumatology*. 2006; **45**:734-40.
- 6 Kaltenhäuser S, Pierer M, Arnold S, et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. *Rheumatology*. 2007; **46**:100-04.
- 7 Harrison MJ, Tricker KJ, Davies L, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. *The Journal of Rheumatology*. 2005; **32**:2330-36.
- 8 Hetland ML, Ejlberg B, Hørslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results

1  
2  
3  
4 from a 2-year randomised controlled trial (CIMESTRA). *Ann Rheum Dis.* 2009;  
5  
6 **68**:384-90.

7  
8  
9 9 Sanmartí R, Gómez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic  
10 progression in early rheumatoid arthritis: a two year prospective study after a structured  
11 therapeutic strategy using DMARDs and very low doses of glucocorticoids. *Clin*  
12 *Rheumatol.* 2007; **26**:1111-18.

13  
14  
15  
16  
17 10 Wagner E, Ammer K, Kolarz G, et al. Predicting factors for severity of rheumatoid  
18 arthritis: a prospective multicenter cohort study of 172 patients over 3 years. *Rheumatol*  
19 *Int.* 2007; **27**:1041-48.

20  
21  
22  
23  
24 11 Combe B, Cantagrel A, Goupille P. Predictive factors of 5-year health assessment  
25 questionnaire disability in early rheumatoid arthritis. *J Rheumatol.* 2003; **30**:2344-49.

26  
27  
28  
29 12 Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for  
30 rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.  
31 *Lancet.* 2004; **364**:263-9.

32  
33  
34  
35 13 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association  
36 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.*  
37 1988; **31**:315-24.

38  
39  
40  
41  
42 14 O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with  
43 methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three  
44 medications. *N Engl J Med.* 1996; **334**:1287-91.

45  
46  
47  
48 15 Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial  
49 arterial wall changes in patients with recent-onset rheumatoid arthritis. *Arthritis Res*  
50 *Ther.* 2009; **11**:R51.

1  
2  
3  
4 16 van der Kooij SM, Allaart CF, Dijkmans BA, et al. Innovative treatment strategies  
5 for patients with rheumatoid arthritis. *Curr Opin Rheumatol*. 2008; **20**:287-94.  
6  
7

8 17 Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy  
9 with conventional disease-modifying antirheumatic drugs can achieve high response  
10 rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-  
11 inflammatory drug use. *Semin Arthritis Rheum*. 2007; **37**:99-111.  
12  
13

14  
15  
16  
17 18 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score  
19 (DAS28) and European League Against Rheumatism response criteria based on C-  
20 reactive protein against disease progression in patients with rheumatoid arthritis, and  
21 comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*.  
22 2009; **68**:954-60.  
23  
24  
25  
26  
27

28 19 Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment  
29 questionnaire (MDHAQ): Assessment of advanced activities of daily living and  
30 psychological status in the patient-friendly health assessment questionnaire format.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

20 Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses  
of disease activity, disease characteristics, and treatments in the QUEST-RA study.  
*Arthritis research & therapy*. 2009; **11**:R7.

21 Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to  
methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-  
label phase of the SWEFOT trial. *Ann Rheum Dis*. 2011; **70**:469-75.

22 Lopez-Bermejo A, Hernandez-Aguado I, Vera IJ, et al. Sex-specific, independent  
associations of insulin resistance with erythrocyte sedimentation rate in apparently  
healthy subjects. *Thrombosis and haemostasis*. 2007; **97**:240-4.

1  
2  
3  
4 23 Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response  
5 to infliximab in rheumatoid arthritis. *Arthritis & Rheumatism*. 2011; **63**:359-64.  
6  
7

8 24 Bartoloni E, Alunno A, Luccioli F, et al. Atherosclerotic vascular damage and  
9 rheumatoid arthritis: a complex but intriguing link. *Expert Rev Cardiovasc Ther*. 2010;  
10 **8**:1309-16.  
11  
12

13 25 Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in  
14 recent onset rheumatoid arthritis: a critical role for inflammation. *Arthritis research &*  
15 *therapy*. 2007; **9**:R116.  
16  
17

18 26 Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced  
19 glycation end products and of S100 proteins are associated with inflammatory,  
20 autoantibody, and classical risk markers of joint and vascular damage in rheumatoid  
21 arthritis. *Arthritis Res Ther*. 2009; **11**:R39.  
22  
23

24 27 Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint  
25 damage in rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2005; **64**:196-201.  
26  
27

28 28 Mäkinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced  
29 radiographic progression with combination disease modifying antirheumatic drugs in  
30 early rheumatoid arthritis. *The Journal of Rheumatology*. 2007; **34**:316-21.  
31  
32

33 29 Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and  
34 remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP  
35 predicted radiographic progression in the 5-year extension of the double-blind  
36 randomised CIMESTR trial. *Ann Rheum Dis*. 2010; **69**:1789-95.  
37  
38

39 30 Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the  
40 management of rheumatoid arthritis with synthetic and biological disease-modifying  
41 antirheumatic drugs. *Ann Rheum Dis*. 2010; **69**:964-75.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 31 Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. *BMC Musculoskelet Disord.* 2009; **10**:71.

32 Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). *Rheumatology.* 2011; **50**:926-31.

33 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010; **62**:2569-81.

**TABLES:****Table 1.** Baseline characteristics of the patients

Baseline variable	Value
Female*	60 (59.4%)
Age <sup>†</sup> , years	54 (12)
Smoking	
Current Smokers	26 (25.7%)
Ex-Smokers	29 (28.7%)
Weight <sup>†</sup> , Kg	77.10 (19.68)
SBP <sup>†</sup> , mm Hg	127 (15)
DBP <sup>†</sup> , mm Hg	73 (10)
RF*	89 (88.1%)
ACPA*	51 (50.5%)
ESR <sup>§</sup> , mm/hour	25 (12, 46)
CRP <sup>§</sup> , mg/liter	9.7 (19, 39)
Lymphocytes <sup>†</sup> , x 10 <sup>9</sup> /L	1.94 (0.67)
Neutrophils <sup>†</sup> , x 10 <sup>9</sup> /L	5.12 (2.50)
LFT (AST) <sup>§</sup> , U/L	20.50 (16.50, 24.00)
LFT (ALT) <sup>§</sup> , U/L	19 (14, 27)
eGFR <sup>§</sup> , mL/min	89 (74, 90)
Glucose <sup>§</sup> , mmol/L	5.2 (4.9, 5.75)

\* Values are n (%); <sup>†</sup> values are the median (SD); <sup>§</sup> values are the median (IQR). SD = standard deviation; IQR = interquartile range; RF = Rheumatoid Factor; SBP = systolic blood pressure; DBP = diastolic blood pressure; ACPA = anti-citrullinated peptide



antibody; ESR = erythrocyte sedimentation ratio; CRP = C reactive protein; LFT = liver function test; AST = aspartate aminotransferase; ALT = alanine aminotransferase; eGFR = estimated glomerular filtration rate.

**Table 2. Change in median pain VAS scores, DAS and HAQ scores (95% CI) over 1 year**

	Baseline	6 month	1 year	Change at 6 months	p	Change at 1 year	p
Pain Score	55 (48, 62)	37.9 (31.7, 44.1)	24.2 (17.7, 30.6)	-21.9 (-30.8, -13)	<0.001	-27.4 (-35.6, -19.1)	<0.001
DAS4v	4.5 (4.1, 4.8)	3.4 (3.1, 3.7)	3.2 (2.9, 3.4)	-1.3 (-1.8, -0.8)	<0.001	-1.5 (-2, -1.1)	<0.001
mHAQ	0.6 (0.5, 0.8)	0.44(0.3, 0.6)	0.3 (0.2, 0.4)	-0.3 (-0.5, -0.1)	0.003	-0.3 (-0.4, -0.2)	<0.001
Proportion of patients with:							
DAS ≤ 2.6	12 (14.8%)	25 (25%)	29 (29%)				
DAS ≤ 3.2	18 (22%)	48 (48%)	52 (52%)				

**Table 3. Frequency of steroid use over the study**

Treated with:	Study duration (weeks)					
	0 (0)	4	8	12	16	24
Oral Steroid n (%)	16 (15.8)	17 (16.8)	14 (13.9)	11 (10.9)	1 (1)	1 (1)
IA steroid	21 (20.7)	2 (2)	4 (0)	2 (2)	0	0
Any steroid	37 (36.7)	19 (18.8)	18 (17.8)	13 (12.9)	1 (1)	1 (1)
Oral and IA steroid	3 (3)	1 (1)	2 (2)	0	0	0

IA intra-articular

**Table 4. Variables influencing DAS scores at 4 and 12 weeks of study – Univariate regression**

	DAS4v		DAS4v	
	Week 4		Week 12	
	$\beta$	p	$\beta$	p
Female	0.68	0.009	0.46	0.059
Smoking				
Ex-smokers vs non-smokers	-0.55	0.026	-0.17	0.53
Current smokers vs non-smokers	-0.80	0.003	-0.42	0.10
LFT (ALT)	0.03	0.01	0.04	0.63
Weight*CRP	0.002	0.029	0.002	0.02
Oral or IA Steroid	0.11	0.67	0.01	0.98
Anti-CCP > 6	0.0004	0.99	0.67	0.08

Values are regression coefficient ( $\beta$ ) and p-value. Regression co-efficient at each time point for RF = 0. CRP = C reactive protein; LFT = liver function test; ALT = alanine aminotransferase.


**Table 5. Effects of time-varying risk factors individually on DAS28 scores over 1 year of study – Univariate regression**

	DAS4v		
	$\beta$	95% CI	p
Female	0.45	0.09, 0.81	0.014
Age	0.001	-0.13, 0.02	0.82
Smoking:			
Ex-smokers vs non-smokers	-0.27	-0.70, 0.16	0.22
Current smokers vs non-smokers	-0.48	-0.91, -0.06	0.026
SBP	0.10	0.08, 0.20	<0.001
DBP	0.10	0.04, 0.20	0.004
Lymphocyte	0.04	-0.09, 0.17	0.55
Neutrophil	0.16	0.10, 0.22	<0.001
ESR	0.03	0.03, 0.04	<0.001
CRP	0.02	0.01, 0.02	<0.001
LFT-AST	-0.004	-0.01, 0.003	0.25
LFT-ALT	-0.003	-0.009, 0.004	0.44
Weight*CRP	0.002	0.001, 0.003	<0.001
Weight*ESR	0.004	0.003, 0.005	<0.001
Oral or IA steroid	0.66	0.34, 0.99	P<0.01
Anti-CCP > 6	0.001	-0.001, 0.002	0.36


Regression co-efficient at each time point for RF = 0.

**FIGURES :**

**Figure 1. Distribution of DAS4v over the study period. A:** The median and 95% CI are plotted for each visit over the 52 week study period. **B:** Changes in DAS4v over 4, 28 and 52 weeks are indicated. **C:** The changing distribution in DAS4v in the sample is plotted at baseline, 4, 28 and 52 weeks.



**Figure 2. Variation in the disease activity parameters over the study period.** The median and 95% CI are plotted for each visit over the 52 week study period for ESR, CRP, tender joint count, swollen joint count, fatigue, morning stiffness, patient global and physician global scores.



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	x
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	x
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	x
Objectives	3	State specific objectives, including any prespecified hypotheses	x
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	x
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	x
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	x
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	x
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	x
Bias	9	Describe any efforts to address potential sources of bias	x
Study size	10	Explain how the study size was arrived at	x
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	x
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	x
		(b) Describe any methods used to examine subgroups and interactions	-
		(c) Explain how missing data were addressed	x
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	x
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	x
		(b) Indicate number of participants with missing data for each variable of interest	x
		(c) Summarise follow-up time (eg, average and total amount)	x
Outcome data	15*	Report numbers of outcome events or summary measures over time	x
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	x

		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	x
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	x
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	x
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	x
Generalisability	21	Discuss the generalisability (external validity) of the study results	x
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	x

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.





**Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003083.R1
Article Type:	Research
Date Submitted by the Author:	03-Jun-2013
Complete List of Authors:	Thomas, Ranjeny; The University of Queensland, Diamantina Institute White, Douglas; The University of Queensland, Diamantina Institute Pahau, Helen; The University of Queensland, Diamantina Institute Duggan, Emily; The University of Queensland, Diamantina Institute Paul, Sanjoy; The University of Queensland, School of Population Health
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Epidemiology, Pharmacology and therapeutics
Keywords:	RHEUMATOLOGY, EPIDEMIOLOGY, STATISTICS & RESEARCH METHODS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Trajectory of intensive treat-to-target disease modifying drug regimen in an**  
5  
6 **observational study of an early rheumatoid arthritis cohort**  
7

8 Douglas White<sup>1</sup>, Helen Pahau<sup>1</sup>, Emily Duggan<sup>1</sup>, Sanjoy Paul\*<sup>2</sup> and Ranjeny Thomas\*<sup>1</sup>  
9  
10

11  
12 <sup>1</sup> - Diamantina Institute, University of Queensland, Princess Alexandra Hospital,  
13 Ipswich Road, Woolloongabba, Queensland, Australia  
14

15  
16 <sup>2</sup> - Queensland Clinical Trials and Biostatistics Centre, School of Population Health,  
17 University of Queensland, Translational Research Institute, Princess Alexandra  
18 Hospital, Queensland, Australia  
19

20  
21 \* These authors contributed equally to the work  
22

23  
24 Corresponding author: Ranjeny Thomas,  
25

26  
27 email: ranjeny.thomas@uq.edu.au  
28

29  
30 Telephone: +61734436960  
31

32  
33 Fax: +61734436966  
34  
35  
36

37  
38 Short title: Trajectory of intensive treat-to-target DMARDs in RA  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

Objectives: Studies of early rheumatoid arthritis (RA) cohorts have analysed treatment response and prognostic factors at fixed time points. However, in treat-to-target protocols, therapeutic decision-making is dynamic, and responsive to disease activity over time. To determine when a minimal residual disease response target should be expected, our primary objective was to identify the time-dependent therapeutic response to combination disease modifying anti-rheumatic drugs (DMARDs) for 12 months. Our secondary objective determined factors affecting this response trajectory. Design: Observational cohort. Setting: Treat-to-target early RA clinic in Australian tertiary referral hospital. Participants: We enrolled consecutive patients attending an early arthritis clinic with symptom duration less than 12 months, who were diagnosed with RA for the first time between 2004 and 2008. One hundred and one met these eligibility criteria and data were available at baseline through 12 months. Interventions: Intensive DMARDs according to a treat-to-target protocol. Primary and secondary outcome measures: We measured disease activity scores (DAS) at each visit, then analysed therapeutic response and associated factors in a time-dependent fashion over 12 months. Results: The median DAS4vESR of 4.46 at baseline decreased 12 weeks later by 24%, while the proportion with DAS4v  $\leq 2.6$  increased ( $p < 0.01$ ). DAS4v continued to decrease over 52 weeks. DAS4v reduction of at least -0.45 at 4 weeks was predictive of DAS4v at 28 and 52 weeks. Female gender, current smoking, primary education and an interaction between baseline weight and CRP negatively impacted DAS4v reduction over 4 and 52 weeks. Time-varying effects of blood pressure, neutrophils, ESR and CRP also significantly influenced DAS4v over 52 weeks. Conclusions: Time-dependent data suggest that the largest reduction of DAS4v to combination DMARDs occurs in the

1  
2  
3  
4 first month of therapy, and this predicts subsequent response. Variables known to  
5 impact long-term treatment response in RA also impacted early DAS4v response to  
6 combination DMARDs.  
7  
8  
9

## 10 **Article Summary**

### 11 Article focus

- 12 • Best-practice early RA treatment aims to achieve a target response. In clinic  
13 settings of many countries, first-line therapies are DMARDs, including  
14 combination DMARDs
- 15 • We followed an observational cohort for 12 months in a treat-to-target early RA  
16 clinic to identify the time-dependent therapeutic response to combination  
17 DMARDs for 12 months and factors affecting this response trajectory  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Key messages**

- 29 • After initiation of combination DMARDs, the largest reduction in disease  
30 activity score occurred in the first month, and its magnitude predicted  
31 subsequent response  
32
- 33 • Disease activity score over 12 months was influenced by female gender and  
34 current smoking, education level and an interactive effect of weight and either  
35 CRP or ESR  
36
- 37 • The data suggest clinical response to combination DMARDs may be more rapid  
38 than previously appreciated, and treatment response in the first month may have  
39 prognostic significance  
40
- 41 • These hypotheses require further testing in other cohorts  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **Strengths and Limitations**

**Strengths**

- Monthly observation allowed precise determination of time-dependent therapeutic response and demonstrated an unexpectedly rapid response to combination DMARDs
- Standardised combination DMARD treat-to-target protocol
- Real-life clinical setting with dynamic therapeutic decision making

**Limitations**

- Observational cohort study limits conclusions that can be drawn regarding causality, without further testing in a randomised controlled trial
- Relatively small cohort derived from a single centre, with treatment regimen determined within Australian prescribing context, and exclusions due to missing data limit generalisability.
- Number of participants limited by lack of baseline or 12 month follow-up data and may have introduced selection bias
- Due to incomplete radiographic data, factors associated with radiographic outcomes could not be determined

**BACKGROUND:**

Intervention with early combination disease modifying anti-rheumatic drug (DMARD) therapy favourably influences progression of rheumatoid arthritis (RA) independent of treatment in later years, suggesting that there is a “window of opportunity” in which the disease process can be altered [1, 2]. Moreover, a good response at 6 months to tight disease control using methotrexate predicted outcome after 5 years of treatment in participants in the CAMERA study [3]. The severity of disease varies in RA patients. In those with aggressive disease, damage to articular structures occurs early in the disease process: erosions were detected in 12.8% of patients after a median of 8 weeks in one study [4]. Thus, early evidence and determinants of treatment response to a given regimen are critical, in order to channel patients at greatest risk of poor outcome to more intensive induction regimens or more expensive biologic therapies within that window.

Studies of prognostic factors by statistical modelling have analysed disease progression outcomes including erosions, disease activity score (DAS28) and disability index as measured by Health Assessment Questionnaire (HAQ) at fixed time points – usually 6 or 12 months, with the earliest being 3 months – to determine treatment response and associated factors influencing this. Factors associated with poor radiological outcome include smoking, rheumatoid factor (RF) positivity, the presence of anti-citrullinated peptide autoantibodies (ACPA), HLA-DR genotype, low socioeconomic status and bone oedema on magnetic resonance imaging [5-9]. On the other hand, poor outcome measured by HAQ was associated with high baseline disease activity or HAQ, including RF, DAS28 score, tender and swollen joint counts, ESR and CRP [10, 11]. However, in treat-to-target protocols, such as was used in the TICORA trial and which occur in real-

1  
2  
3  
4 life clinic settings, decision-making about dose and drugs is a dynamic process,  
5  
6 responsive to the patient's disease activity over time [12]. In many early arthritis  
7  
8 protocols, including the current study, patients are treated and monitored intensively  
9  
10 during the first 3-6 months, followed by a reduced visit frequency. Longitudinal  
11  
12 analysis of all available data, while modelling the trajectories and drawing inferences on  
13  
14 the significance of various risk factors, provides higher power and better insight into the  
15  
16 dynamic process.  
17  
18  
19  
20

### 21 22 **AIMS:**

23  
24 In the current study, our primary objective was to identify the time-dependent  
25  
26 therapeutic response in an observational study of combination DMARDs for 12 months  
27  
28 in order to determine when a minimal residual disease response target should be  
29  
30 expected. Our secondary objective was to determine factors affecting this response  
31  
32 trajectory. We therefore gathered disease activity data at each treatment visit then  
33  
34 analyzed the disease activity response in a time-dependent fashion. We then determined  
35  
36 factors which influenced this time-dependent response to an intensive DMARD  
37  
38 regimen.  
39  
40  
41  
42

### 43 44 **METHODS:**

45  
46 We enrolled consecutive patients referred by general practitioners from a relatively  
47  
48 socio-economically disadvantaged catchment (60% referrals of employed individuals  
49  
50 working in manual industries) to an early arthritis clinic in a public teaching hospital,  
51  
52 with symptom duration less than 2 years, who were diagnosed with RA for the first time  
53  
54 between 2004 and 2008. Patients were selected for inclusion in the current study if data  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 were available at baseline through 12 months; however data were not required at every  
5  
6 time point for inclusion. Two hundred and six patients were referred with possible RA  
7  
8 and 101 patients met these eligibility criteria; 49 did not have RA, and 54 patients who  
9  
10 met all other criteria were excluded as data were unavailable at 12 months. Of these, 7  
11  
12 were seen once and diagnosed with RA then treated elsewhere, and the remainder were  
13  
14 reviewed at least once but not at 12 months. All study participants met the American  
15  
16 College of Rheumatology 1987 revised criteria for the classification of RA [13]. Ethical  
17  
18 approval for retrospective data analysis was obtained from the Metro South Human  
19  
20 Research Ethics Committee.  
21  
22  
23  
24

25  
26 Referrals from local general practitioners were triaged within 1 week, and patients were  
27  
28 generally diagnosed within the next 4 weeks. Since full clinical and laboratory  
29  
30 evaluation was available at the first visit to the early arthritis clinic, patients received  
31  
32 combination methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ)  
33  
34 [14], unless contraindicated, immediately after diagnosis and confirmation of RA by the  
35  
36 treating rheumatologist. Treatment was intensified according to a response-driven step-  
37  
38 up algorithm, as previously described [15], with remission as the target [16, 17].  
39  
40 Briefly, criteria for dose escalation were either >2 swollen joints and abnormal ESR or  
41  
42 CRP, or at least 2 of the following 4 criteria: morning stiffness >30mins, pain or fatigue  
43  
44 visual analogue scale (VAS) >30mm, or >2 tender joints. The following medications  
45  
46 were prescribed at baseline: MTX 10mg/week, folic acid 5mg/week, SSZ 500mg daily  
47  
48 increasing by 500mg at weekly intervals to 1000mg twice daily, HCQ 200mg daily for  
49  
50 one week then 400mg daily thereafter. Patients were seen at 4-weekly intervals and the  
51  
52 MTX dose was escalated according to treatment response at a conservative rate by 5mg  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 at each visit to a maximum of 25mg weekly. If disease remained active on this  
5  
6 combination, SSZ was stopped, MTX reduced to 10mg weekly and leflunomide started  
7  
8 at a dose of 20mg daily. MTX dose was titrated back to 25mg weekly, and if this  
9  
10 combination failed and the Australian Pharmaceutical Benefit Scheme criteria were met,  
11  
12 the patient commenced biologic therapy. Based on these criteria, 10% of patients in this  
13  
14 setting commenced biologics per year. In general, the use of NSAIDs and oral  
15  
16 corticosteroids was minimized, but intra-articular or oral steroids could be administered  
17  
18 at the discretion of the treating physician. Large joints were injected with 40-80mg  
19  
20 DepoMedrol and smaller joints with 1ml (5.7mg) Celestone. Oral and intra-articular  
21  
22 dosage of corticosteroids was recorded monthly.  
23  
24  
25  
26  
27

28 Response to therapy was measured as follows: the 4 variable DAS28ESR (hereafter  
29  
30 referred to as DAS4v) was used as an index of inflammatory control [18], and the  
31  
32 mHAQ as an index of disability [19]. Each index was calculated at each visit: baseline,  
33  
34 and weeks 4, 8, 12, 16, 22, 28, 36, 44 and 52.  
35  
36  
37  
38

39 Demographic details were ascertained by questionnaire and included: age at  
40  
41 presentation, symptom duration, level of education, gender, current, ex-smokers and  
42  
43 non-smokers and mHAQ. Patients completed VAS for pain, fatigue and their global  
44  
45 assessment of disease. The 28 tender and swollen joint counts, height, weight and blood  
46  
47 pressure (BP) were recorded by the clinical research nurse. Blood was collected at  
48  
49 baseline for the analysis of ESR, CRP, LFT, FBC, RF and ACPA. ACPA were  
50  
51 measured at Queensland Health Pathology using the anti-CCP2 ELISA (Axis-Shield)  
52  
53 test, with the cut-off of 6 for a positive test.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Basic statistics were presented by number (%) or mean (SD) or median (IQR), as  
7 appropriate. Five imputations for missing data on clinical, biochemical and score data  
8 were performed using Bayesian Markov chain Monte Carlo multiple-imputation  
9 technique. Of those who met eligibility criteria for study inclusion, not all patients  
10 attended for all visits, however the patterns of missingness were random for all the  
11 study parameters. The consistency in the distributions of the 5 imputed data was  
12 checked for all study parameters. Given the skewed DAS and mHAQ scores, the  
13 medians and their 95% confidence intervals (CI) are presented. The changes in these  
14 scores over the study period are presented by median and 95% CI. Significance levels (p  
15 values) are based on the appropriate non-parametric test.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Generalized multivariate linear regression models with Gamma distribution and Identity  
31 link were used to identify the statistically significant ( $p \leq 0.10$ ) risk factors and their  
32 possible interaction effects on disease activity scores at week 4 of the study. The  
33 possible consistency in the effect sizes of the statistically significant risk factors (at  
34 week 4) were also assessed on the disease activity scores at week 12 of the study.  
35 Combining the 10 longitudinal measurements obtained over one year of the study, the  
36 time varying effects of individual risk factors on the disease activity scores were  
37 explored using generalized estimating equation (GEE) regression approach with  
38 Gamma distribution and identity link function under the assumption of 'unstructured'  
39 correlation structure.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**RESULTS:****Time-dependent therapeutic response to combination DMARDs for 12 months**

One hundred and one patients were included in the study and 54 (of whom 7 were only seen once) were excluded due to missing 12 month follow-up data. The baseline characteristics of included and excluded patients are shown in Table 1. Except for a lower systolic BP in excluded subjects, there were no significant differences between included and excluded subjects. All except 4 patients took at least two and up to three of the following DMARDs in combination during the 12 months study: Methotrexate, Sulfasalazine, Hydroxychloroquine and Leflunomide. These 4 patients took Methotrexate monotherapy.

The median disease activity score at baseline was 4.46 for DAS4v (Table 2). Four of the 12 patients with baseline DAS  $\leq 2.6$  (minimal disease activity) were taking steroids prior to referral. There was a highly significant ( $p < 0.001$ ) DAS reduction of 24% at 28 weeks (Table 2). We also observed a significant increase in the proportion of patients with minimal residual, (DAS28  $\leq 2.6$ ) and low disease (DAS28  $\leq 3.2$ ) over the treatment period ( $p < 0.01$ ) (Table 2). Consistent with this, the patients' pain scores improved highly significantly by 31% and 56% at the end of 6-month and one-year of treatment respectively. The improvement in mHAQ from baseline to 6 months, but not between 6 and 12 months of treatment, was significant. The average annual change was 0.30 units (Table 2).

Analysis of the change in DAS4v over time showed a progressive reduction over 52 weeks, with the steepest drop between baseline and 4 weeks (Figure 1). The median

1  
2  
3  
4 (95% CI) of changes in DAS4v at 4, 28 and 52 weeks were -0.45 (-0.84, -0.07), -0.86 (-  
5  
6 1.30, -0.41), and -1.35 (-1.67, -1.03) respectively ( $p < 0.01$  at week 52). The changing  
7  
8 patterns of the distribution of DAS4v over time are evident from the density plots in  
9  
10 Figure 2. Although a significant shift in the distribution of DAS4v at 4 weeks from  
11  
12 baseline is evident from the density plot, the distributions overlap at 4, 28 and 52 weeks.

13  
14  
15  
16  
17 Analysis of the individual components of the DAS over this period demonstrated that  
18  
19 patient global score, swollen and tender joint counts all fell most steeply between  
20  
21 baseline and 4 weeks (Figure 2). While this was not the case for the fall in either ESR or  
22  
23 CRP, similar steep falls in fatigue score, morning stiffness and physician global scores  
24  
25 occurred between baseline and 4 weeks. Thus most measures of disease activity fell  
26  
27 most rapidly in the first 4 weeks after DMARD initiation. In contrast, ESR fell for 3  
28  
29 months before reaching a plateau, while CRP fell progressively for 6 months.

### 30 31 32 33 34 35 **Factors affecting the response trajectory in early RA patients treated with** 36 37 **combination DMARDs**

38  
39 To determine whether the fall in DAS4v at 4 weeks predicted the DAS at 28 and 52  
40  
41 weeks, we first calculated that the median level of change in DAS4v at 4 weeks was -  
42  
43 0.45. This was clinically discriminatory: at 4 weeks, 52% had no change or an increase  
44  
45 in DAS4v while 48% improved from baseline DAS4v. The number and proportion of  
46  
47 patients receiving steroids is indicated in Table 3. While baseline steroids impacted the  
48  
49 likelihood of improvement at 4 weeks, this was not statistically significant (69% of  
50  
51 patients receiving steroids improved and 53% not receiving steroids improved; odds  
52  
53 ratio for improvement with steroids 1.95,  $p = 0.12$ ). Patients with reduction in DAS4v at  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 4 weeks of at least -0.45 were three times more likely [OR (95% CI): 3.10 (1.2, 8.0)] at  
5  
6 28 weeks and 17 times more likely [OR (95% CI): 17.14 (4.52, 64.94)] at 52 weeks to  
7  
8 maintain the same or reduced DAS4v as achieved after 4 weeks of treatment. Univariate  
9  
10 modelling of factors affecting outcome showed that female sex, smoking status and  
11  
12 increasing ALT at baseline negatively affected DAS4v at 4 weeks, but these effects  
13  
14 became less significant by 12 weeks (Table 4). An interaction between baseline weight  
15  
16 and CRP negatively affected DAS at both week 4 and 12. Patients taking steroid did not  
17  
18 have a significantly different disease score, and symptom duration before RA diagnosis,  
19  
20 anti-CCP or RF titre did not impact 4 week DAS. The reduction in DAS4v at 4 weeks  
21  
22 was significantly greater in patients with tertiary than with primary education.  
23  
24  
25  
26  
27

28  
29 Combining baseline characteristics and the longitudinal measurements obtained over  
30  
31 one year, we explored the time varying effects of individual risk factors on DAS4v in a  
32  
33 univariate model. DAS4v over 52 weeks was again influenced by female gender and  
34  
35 current smoking, and an interactive effect of weight and either CRP or ESR. Time  
36  
37 varying effects of systolic and diastolic blood pressure, neutrophil counts, ESR and  
38  
39 CRP also significantly influenced DAS4v observed over 52 weeks (Table 4). At week  
40  
41 52, the largest reduction in DAS4v was observed in patients with tertiary education  
42  
43 (3.57), compared with that observed among patients with secondary (2.56) or primary  
44  
45 education (1.33). Symptom duration prior to diagnosis did not significantly influence  
46  
47 DAS4v over 52 weeks. Over the course of the study, DAS4v was increased by 0.66 in  
48  
49 those patients taking steroids ( $p < 0.01$ ). These data are in keeping with the use of  
50  
51 steroid in this study at the clinician's discretion, to provide additional control for disease  
52  
53 activity that was not controlled by the DMARD protocol.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 We found that the relationship between mHAQ and DAS4v for the cohort was  
7 significantly correlated at baseline, 4 weeks, 28 weeks and 52 weeks ( $p < 0.001$ ), with  
8 this correlation becoming progressively tighter over time as DAS and mHAQ fell. Thus,  
9 functional outcome after 1 year of early RA treatment is highly dependent on  
10 achievement of low disease activity.  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **DISCUSSION:**

21 Our study describes the response of a group of patients with early RA to intensive  
22 conventional DMARD therapy in a time-dependent fashion over the first year. Baseline  
23 characteristics were in line with previous cohorts of patients with early RA. However,  
24 our baseline DAS scores were relatively low, reflecting our rapid triage and clinical and  
25 laboratory assessment of early arthritis referrals. Surprisingly, the time-dependent  
26 analysis of DAS response showed that the majority of disease activity measures fall  
27 most rapidly in the first 4 weeks after commencing intensive DMARD treatment in this  
28 population. There was a subsequent slow and progressive reduction in DAS until week  
29 52. This fall in DAS4v at 4 weeks appeared to be clinically meaningful, as it predicted  
30 the DAS at 28 and 52 weeks. This observation suggests that for patients who failed to  
31 respond within 4 weeks to combination DMARD treatment, few gains were made by  
32 continuing to apply the same DMARD treat-to-target algorithm for 6-12 months. This  
33 was reflected in the similar proportion of patients with minimal or low disease activity  
34 between 6 and 12 months. By this stage patients had progressed through the  
35 combination DMARD algorithm, for which the next step would be biologics. However,  
36 because their disease activity is minimal or low, they failed to qualify for biologics  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 based on Australia's Pharmaceutical Benefit Scheme (PBS) requirements  
5  
6 (<http://www.medicareaustralia.gov.au/provider/pbs/drugs2/rheumatoid.jsp>) [20]. On the  
7  
8 other hand, our data suggest the hypothesis that continued effort in applying a treat-to-  
9  
10 target combination DMARD algorithm is likely to be effective over the ensuing months  
11  
12 in patients who make a moderate response by week 4. Our data further suggest that  
13  
14 combination DMARDs act unexpectedly rapidly in this early RA population, as  
15  
16 patients' use of steroids did not influence the reduction in DAS. In support of this  
17  
18 conclusion regarding steroids, in a study of 61 patients with early RA treated according  
19  
20 to a similar response-driven step-up combination DMARD algorithm, Proudman *et al*  
21  
22 obtained an almost identical 6 month minimal disease activity rate (DAS28<2.6 in  
23  
24 29%), despite infrequent use of corticosteroids [17].  
25  
26  
27  
28  
29

30  
31 The current study has a number of limitations. Firstly, our interpretation that the  
32  
33 magnitude of the fall in DAS4v after 1 month predicts 1 year outcome is limited by the  
34  
35 observational study design. However, the question of whether outcome could be  
36  
37 improved in patients with a minimal treatment response within 1 month could be tested  
38  
39 in a randomised controlled trial comparing switch to biologic therapy with continued  
40  
41 combination DMARDs. Secondly, this is a relatively small cohort derived from a single  
42  
43 centre with referrals derived from a relatively socio-economically disadvantaged  
44  
45 catchment, with the treatment regimen determined within the Australian prescribing  
46  
47 context. At the time of recruitment, 1987 ACR criteria were used to diagnose RA,  
48  
49 which would have limited capacity to diagnose less severe patients. The number of  
50  
51 participants was limited by lack of baseline or 12 month follow-up data and this may  
52  
53 have introduced selection bias towards a more compliant group. The small sample size  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 and number of exclusions due to incomplete data limit generalisability to other  
5  
6 prescribing environments or clinical settings, and further studies are needed to test the  
7  
8 generalisability of our findings. For example it is possible that those excluded had a  
9  
10 different disease trajectory due to differences risk for poor outcome or differences in  
11  
12 adverse events. A sub-analysis of the trajectory excluded patients was not possible  
13  
14 because of the low number of paired baseline and 4 week DAS4v measurements in this  
15  
16 group. On the other hand, there were no differences in the baseline characteristics of the  
17  
18 excluded patients (except systolic BP). Furthermore, almost all factors associated with 4  
19  
20 week DAS4v response have been previously demonstrated to affect disease outcome in  
21  
22 longer-term and larger studies. The strengths of this study are that it analyses real-  
23  
24 world data, monthly observations allowed precise determination of time-dependent  
25  
26 response, and patients received a standardised combination DMARD treat-to-target  
27  
28 protocol, reducing the confounding effect of treatment decisions based on individual  
29  
30 clinician preference.  
31  
32  
33  
34  
35  
36

37 The exploratory nature of the study in a relatively small sample could introduce false  
38  
39 positive associations. Although it possible that the rapid 4 week response to  
40  
41 combination DMARDs represents regression to the mean, the continued good response  
42  
43 of these patients argues against this. Our data also are consistent with recent studies  
44  
45 demonstrating that early good response to combination therapy (in the TEAR and  
46  
47 RAPID 1 trials) is associated with a continued good response [21, 22]. In these studies,  
48  
49 rapid response was ascertained 12 weeks after initiation of combination therapy. By  
50  
51 regression analysis, we identified female gender, current smoking, education level, ALT  
52  
53 and an interaction between weight and CRP as significant determinants of disease  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 activity over 4 and 52 weeks. Females, current smokers and low levels of education  
5  
6 were found in several studies, including those of early RA, to achieve lower reductions  
7  
8 in disease activity or remission [23-26]. However, no study has previously determined  
9  
10 that the impact of these variables may occur within weeks of commencing treatment.  
11  
12 The interaction between weight and inflammation in RA is intriguing and has been  
13  
14 noted previously in insulin resistant states [27]. In patients with active RA, those with  
15  
16 high BMI responded less well to infliximab [28]. We also identified significant time-  
17  
18 varying effects of blood pressure, gender, age, weight and inflammatory markers on  
19  
20 disease activity. The interaction between disease activity and cardiovascular risk is well  
21  
22 documented in RA, including early RA, and traditional cardiovascular risk factors may  
23  
24 also impact the activity of inflammatory disease over time [15, 29-31]. However, it is  
25  
26 unknown whether control of cardiovascular risk factors can in turn impact inflammatory  
27  
28 disease control.  
29  
30  
31  
32  
33  
34

35 In this study we were limited to analysis of disease and functional score, as radiographic  
36  
37 data were not sufficiently complete to allow measurement of structural damage.  
38  
39 However, this issue has been addressed by others, where biomarkers such as ACPA  
40  
41 antibodies, RF, CRP and cartilage oligomeric matrix protein can add power to  
42  
43 predictive models of bone erosion in early RA [32]. In contrast, we found no impact of  
44  
45 ACPA or RF on DAS. Our data confirm a strong relationship between disease activity  
46  
47 and functional score that appears to strengthen over time, a finding that is supported by  
48  
49 data from the BeST cohort [16]. We would anticipate that functional disability would be  
50  
51 minimized by early treatment with combination DMARDs as shown previously [33,  
52  
53 34].  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Since they are traditionally thought to be slow acting, previous studies of DMARD  
7  
8 monotherapy in early RA have not analyzed time-dependent data from 4 weeks.  
9  
10 Although it remains possible that a similar response might be observed in some patients  
11  
12 starting DMARD monotherapy, we suggest this rapid response may be a unique feature  
13  
14 of intensive combination DMARDs (with multiple mechanisms of action) initiation in  
15  
16 early RA, which is the RA population most responsive to therapeutic intervention [35,  
17  
18 36]. The risks and benefits of intensive DMARD therapy (combinations allowing  
19  
20 switching to achieve tight control) versus monotherapy in early RA deserve further  
21  
22 study, considering inconsistent evidence to support combination DMARD therapy in  
23  
24 RA [36, 37]. The need to identify patients with more aggressive disease prompted one  
25  
26 group to undertake a trial of a stratified treatment plan based on the likelihood of  
27  
28 persistent arthritis, with the aim of minimizing over- and under-treatment in early RA  
29  
30 [38]. Our data suggest the hypothesis that very early response to an intensive DMARD  
31  
32 strategy that minimizes under-treatment predicts response for the first year.  
33  
34  
35

36  
37 Data from the ERAN study show that patients with moderate disease activity at 1 year  
38  
39 are unlikely to achieve better control of their disease if the same protocol is continued,  
40  
41 and a good response at 6 months in the CAMERA study predicted outcome at 5 years  
42  
43 [3, 39]. Our data, collected in a cohort of early RA patients with relatively low baseline  
44  
45 DAS, likely reflect the trajectory of patients meeting criteria for RA early in disease,  
46  
47 and which would be captured in organized clinical settings using the recently-published  
48  
49 new classification criteria [40].  
50  
51  
52  
53  
54

## 55 **CONCLUSIONS :**

56  
57  
58  
59  
60

1  
2  
3  
4 With the availability of increasing numbers of treatment options, application of  
5  
6 strategies that identify early non-responders to intensive DMARD combinations, has  
7  
8 clear implications for treatment stratification within the window of opportunity. Time-  
9  
10 dependent data suggest clinical response to combination DMARDs may be more rapid  
11  
12 than previously appreciated, and treatment response in the first month may have  
13  
14 prognostic significance. Confirmation in other cohorts will be required to determine the  
15  
16 generalisability of this notion.  
17

#### 18 19 **DATA SHARING, COMPETING INTERESTS AND FUNDING**

20  
21 No additional data are available. The authors declare no competing interests in relation  
22  
23 to this article. Supported by NHMRC grants 351439 and 569938. R.T. is supported by  
24  
25 Arthritis Queensland and an ARC Future Fellowship.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

- 1 Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet* 1999;**353**:1568-73.
- 2 Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;**350**:309-18.
- 3 Bakker MF, Jacobs JW, Welsing PM, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. *Ann Rheum Dis* 2011;**70**:1099-103.
- 4 Machold KP, Stamm TA, Eberl GJ, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. *J Rheumatol* 2002;**29**:2278-87.
- 5 Harrison MJ, Tricker KJ, Davies L, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. *J Rheumatol* 2005;**32**:2330-6.
- 6 Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. *Rheumatology (Oxford)* 2006;**45**:734-40.
- 7 Kaltenhauser S, Pierer M, Arnold S, et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. *Rheumatology (Oxford)* 2007;**46**:100-4.
- 8 Hetland ML, Ejjbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results

1  
2  
3  
4 from a 2-year randomised controlled trial (CIMESTRA). *Ann Rheum Dis* 2009;**68**:384-  
5  
6 90.

7  
8  
9 9 Sanmarti R, Gomez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic  
10 progression in early rheumatoid arthritis: a two year prospective study after a structured  
11 therapeutic strategy using DMARDs and very low doses of glucocorticoids. *Clin*  
12 *Rheumatol* 2007;**26**:1111-8.

13  
14  
15  
16  
17 10 Combe B, Cantagrel A, Goupille P. Predictive factors of 5-year health assessment  
18 questionnaire disability in early rheumatoid arthritis. *J Rheumatol* 2003;**30**:2344-49.

19  
20  
21 11 Wagner E, Ammer K, Kolarz G, et al. Predicting factors for severity of rheumatoid  
22 arthritis: a prospective multicenter cohort study of 172 patients over 3 years. *Rheumatol*  
23 *Int* 2007;**27**:1041-8.

24  
25  
26  
27  
28 12 Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for  
29 rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.  
30  
31 *Lancet* 2004;**364**:263-9.

32  
33  
34  
35 13 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association  
36 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*  
37 1988;**31**:315-24.

38  
39  
40  
41 14 O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with  
42 methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three  
43 medications. *N Engl J Med* 1996;**334**:1287-91.

44  
45  
46  
47  
48 15 Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial  
49 arterial wall changes in patients with recent-onset rheumatoid arthritis. *Arthritis Res*  
50 *Ther* 2009;**11**:R51.

1  
2  
3  
4 16 van der Kooij SM, Allaart CF, Dijkmans BA, et al. Innovative treatment strategies  
5 for patients with rheumatoid arthritis. *Curr Opin Rheumatol* 2008;**20**:287-94.  
6  
7

8 17 Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy  
9 with conventional disease-modifying antirheumatic drugs can achieve high response  
10 rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-  
11 inflammatory drug use. *Semin Arthritis Rheum* 2007;**37**:99-111.  
12  
13  
14

15  
16  
17 18 Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score  
19 (DAS28) and European League Against Rheumatism response criteria based on C-  
20 reactive protein against disease progression in patients with rheumatoid arthritis, and  
21 comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*  
22 2009;**68**:954-60.  
23  
24  
25  
26  
27

28 19 Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment  
29 Questionnaire (MDHAQ): assessment of advanced activities of daily living and  
30 psychological status in the patient-friendly health assessment questionnaire format.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 20 Lu CY, Williams KM, Day RO. Has the use of disease-modifying anti-rheumatic  
45 drugs changed as a consequence of controlled access to high-cost biological agents  
46 through the Pharmaceutical Benefits Scheme? *Intern Med J* 2007;**37**:601-6.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

21 van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial  
change in disease activity score 28 predicts the likelihood of achieving low disease  
activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-  
hoc analysis of the RAPID 1 trial. *J Rheumatol* 2012;**39**:1326-33.

1  
2  
3  
4 22 Curtis JR, McVie T, Mikuls TR, et al. Clinical Response Within 12 Weeks as a  
5  
6 Predictor of Future Low Disease Activity in Patients with Early RA: Results from the  
7  
8 TEAR Trial. *J Rheumatol* 2013;**40**:572-8.  
9

10  
11 23 Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses  
12  
13 of disease activity, disease characteristics, and treatments in the QUEST-RA study.  
14  
15 *Arthritis Res Ther* 2009;**11**:R7.  
16

17  
18 24 Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to  
19  
20 methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-  
21  
22 label phase of the SWEFOT trial. *Ann Rheum Dis* 2011;**70**:469-75.  
23

24  
25 25 Socioeconomic deprivation and rheumatoid disease: what lessons for the health  
26  
27 service? ERAS Study Group. Early Rheumatoid Arthritis Study. *Ann Rheum Dis*  
28  
29 2000;**59**:794-9.  
30

31  
32 26 Vliet Vlieland TP, Buitenhuis NA, van Zeben D, et al. Sociodemographic factors and  
33  
34 the outcome of rheumatoid arthritis in young women. *Ann Rheum Dis* 1994;**53**:803-6.  
35

36  
37 27 Lopez-Bermejo A, Hernandez-Aguado I, Vera IJ, et al. Sex-specific, independent  
38  
39 associations of insulin resistance with erythrocyte sedimentation rate in apparently  
40  
41 healthy subjects. *Thromb Haemost* 2007;**97**:240-4.  
42

43  
44 28 Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response  
45  
46 to infliximab in rheumatoid arthritis. *Arthritis Rheum* 2011;**63**:359-64.  
47

48  
49 29 Bartoloni E, Alunno A, Luccioli F, et al. Atherosclerotic vascular damage and  
50  
51 rheumatoid arthritis: a complex but intriguing link. *Expert Rev Cardiovasc Ther*  
52  
53 2010;**8**:1309-16.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 30 Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in  
5 recent onset rheumatoid arthritis: a critical role for inflammation. *Arthritis Res Ther*  
6 2007;**9**:R116.  
7  
8

9  
10 31 Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced  
11 glycation end products and of S100 proteins are associated with inflammatory,  
12 autoantibody, and classical risk markers of joint and vascular damage in rheumatoid  
13 arthritis. *Arthritis Res Ther* 2009;**11**:R39.  
14  
15

16  
17 32 Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint  
18 damage in rheumatoid arthritis. *Ann Rheum Dis* 2005;**64**:196-201.  
19  
20

21  
22 33 Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced  
23 radiographic progression with combination disease modifying antirheumatic drugs in  
24 early rheumatoid arthritis. *J Rheumatol* 2007;**34**:316-21.  
25  
26

27  
28 34 Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and  
29 remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted  
30 radiographic progression in the 5-year extension of the double-blind randomised  
31 CIMESTRA trial. *Ann Rheum Dis* 2010;**69**:1789-95.  
32  
33

34  
35 35 Geletka R, St Clair EW. Treatment of early rheumatoid arthritis. *Best Pract Res Clin*  
36 *Rheumatol* 2003;**17**:791-809.  
37  
38

39  
40 36 Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness  
41 study of oral triple therapy versus etanercept plus methotrexate in early aggressive  
42 rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 37 Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the  
5 management of rheumatoid arthritis with synthetic and biological disease-modifying  
6 antirheumatic drugs. *Ann Rheum Dis* 2010;**69**:964-75.  
7  
8

9  
10 38 Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target  
11 therapies in patients with recent onset arthritis; design of a prospective randomized  
12 multicenter controlled trial. *BMC Musculoskelet Disord* 2009;**10**:71.  
13  
14

15  
16 39 Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with  
17 continued conventional therapy for moderate disease activity--the early RA network  
18 (ERAN). *Rheumatology (Oxford)* 2011;**50**:926-31.  
19  
20  
21

22 40 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification  
23 criteria: an American College of Rheumatology/European League Against Rheumatism  
24 collaborative initiative. *Arthritis Rheum* 2010;**62**:2569-81.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**TABLES:****Table 1.** Baseline characteristics of the patients

Baseline variable	Value	
	Included patients (n=101)	Excluded patients (n=54)
Female*	60 (59.4%)	44 (81%)
Age <sup>†</sup> , years	54 (12)	48 (15)
Symptom duration, months <sup>§</sup>	12 (5, 12)	6 (4, 12)
Smoking		
Current Smokers	26 (25.7%)	8 (15%)
Ex-Smokers	29 (28.7%)	26 (48%)
Education		
Primary		5 (14%)
Secondary		24 (66%)
Tertiary		9 (24%)
Weight <sup>†</sup> , Kg	77.10 (19.68)	80 (24)
SBP <sup>†</sup> , mm Hg	127 (15)	120 (17)**
DBP <sup>†</sup> , mm Hg	73 (10)	70 (10)
RF*	89 (88.1%)	42 (77%)
ACPA*	51 (50.5%)	9 (36%)
ESR <sup>§</sup> , mm/hour	25 (12, 46)	16 (10, 34)
CRP <sup>§</sup> , mg/liter	9.7 (19, 39)	6 (2, 12)
Lymphocytes <sup>†</sup> , x 10 <sup>9</sup> /L	1.94 (0.67)	2.1 (1.3, 2.5)
Neutrophils <sup>†</sup> , x 10 <sup>9</sup> /L	5.12 (2.50)	5 (3, 6.8)
LFT (AST) <sup>§</sup> , U/L	20.50 (16.50, 24.00)	18.5 (17, 23)

1  
2  
3  
4 LFT (ALT)<sup>§</sup>, U/L 19 (14, 27) 19 (14, 23)  
5  
6  
7  
8  
9

---

10 \* Values are n (%); † values are the median (SD); § values are the median (IQR). SD =  
11 standard deviation; IQR = interquartile range; RF = Rheumatoid Factor; ACPA = anti-  
12 citrullinated peptide antibody; ESR = erythrocyte sedimentation ratio; CRP = C reactive  
13 protein; LFT = liver function test; AST = aspartate aminotransferase; ALT = alanine  
14 aminotransferase\*\*p=0.002..  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2. Change in median pain VAS scores, DAS and HAQ scores (95% CI) over****1 year**

	Baseline	6 month	1 year	Change at 6 months	p	Change at 1 year	p
Pain	55	37.9	24.2	-21.9	<0.001	-27.4	<0.001
Score	(48, 62)	(31.7, 44.1)	(17.7, 30.6)	(-30.8, -13)		(-35.6, -19.1)	
DAS4v	4.5	3.4	3.2	-1.3	<0.001	-1.5	<0.001
	(4.1, 4.8)	(3.1, 3.7)	(2.9, 3.4)	(-1.8, -0.8)		(-2, -1.1)	
mHAQ	0.6	0.44(0.3, 0.6)	0.3	-0.3	0.003	-0.3	<0.001
	(0.5, 0.8)		(0.2, 0.4)	(-0.5, -0.1)		(-0.4, -0.2)	
Proportion of patients with:							
DAS ≤ 2.6	12 (14.8%)	25 (25%)	29 (29%)				
DAS ≤ 3.2	18 (22%)	48 (48%)	52 (52%)				

**Table 3. Frequency of steroid use over the study**

Treated with:	Study duration (weeks)					
	0 (0)	4	8	12	16	24
Oral Steroid n (%)	16 (15.8)	17 (16.8)	14 (13.9)	11 (10.9)	1 (1)	1 (1)
IA steroid	21 (20.7)	2 (2)	4 (4)	2 (2)	0	0
Any steroid	37 (36.7)	19 (18.8)	18 (17.8)	13 (12.9)	1 (1)	1 (1)
Oral and IA steroid	3 (3)	1 (1)	2 (2)	0	0	0

IA intra-articular

**Table 4. Variables influencing DAS scores at 4 and 12 weeks of study – Univariate regression**

	DAS4v		DAS4v	
	Week 4		Week 12	
	$\beta$	p	$\beta$	p
Female	0.68	0.009	0.46	0.059
Smoking				
Ex-smokers vs non-smokers	-0.55	0.026	-0.17	0.53
Current smokers vs non-smokers	-0.80	0.003	-0.42	0.10
LFT (ALT)	0.03	0.01	0.04	0.63
Weight*CRP	0.002	0.029	0.002	0.02
Oral or IA Steroid	0.11	0.67	0.01	0.98
Anti-CCP > 6	0.0004	0.99	0.67	0.08

Values are regression coefficient ( $\beta$ ) and p-value. Regression co-efficient at each time point for RF = 0. CRP = C reactive protein; LFT = liver function test; ALT = alanine aminotransferase.


**Table 5. Effects of time-varying risk factors individually on DAS28 scores over 1 year of study – Univariate regression**

	DAS4v		
	$\beta$	95% CI	p
Female	0.45	0.09, 0.81	0.014
Age	0.001	-0.13, 0.02	0.82
Smoking:			
Ex-smokers vs non-smokers	-0.27	-70, 0.16	0.22
Current smokers vs non-smokers	-0.48	-0.91, -0.06	0.026
SBP	0.10	0.08, 0.20	<0.001
DBP	0.10	0.04, 0.20	0.004
Lymphocyte	0.04	-0.09, 0.17	0.55
Neutrophil	0.16	0.10, 0.22	<0.001
ESR	0.03	0.03, 0.04	<0.001
CRP	0.02	0.01, 0.02	<0.001
LFT-AST	-0.004	-0.01, 0.003	0.25
LFT-ALT	-0.003	-0.009, 0.004	0.44
Weight*CRP	0.002	0.001, 0.003	<0.001
Weight*ESR	0.004	0.003, 0.005	<0.001
Oral or IA steroid	0.66	0.34, 0.99	P<0.01
Anti-CCP > 6	0.001	-0.001, 0.002	0.36

Regression co-efficient at each time point for RF = 0.


## FIGURES :

**Figure 1. Distribution of DAS4v over the study period. A:** The median and 95% CI are plotted for each visit over the 52 week study period. **B:** Changes in DAS4v over 4, 28 and 52 weeks are indicated. **C:** The changing distribution in DAS4v in the sample is plotted at baseline, 4, 28 and 52 weeks.





**Figure 2. Variation in the disease activity parameters over the study period.** The median and 95% CI are plotted for each visit over the 52 week study period for ESR, CRP, tender joint count, swollen joint count, fatigue, morning stiffness, patient global and physician global scores.



1  
2  
3  
4  
5  
6  
7 **Trajectory of intensive treat-to-target disease modifying drug regimen in an**  
8 **observational study of an early rheumatoid arthritis cohort**  
9

10 Douglas White<sup>1</sup>, Helen Pahau<sup>1</sup>, Emily Duggan<sup>1</sup>, Sanjoy Paul<sup>\*2</sup> and Ranjeny Thomas<sup>\*1</sup>  
11  
12

13  
14  
15 <sup>1</sup> - Diamantina Institute, University of Queensland, Princess Alexandra Hospital,  
16 Ipswich Road, Woolloongabba, Queensland, Australia  
17

18 <sup>2</sup> - Queensland Clinical Trials and Biostatistics Centre, School of Population Health,  
19 University of Queensland, Translational Research Institute, Princess Alexandra  
20 Hospital, Queensland, Australia  
21  
22

23 \* These authors contributed equally to the work  
24

25 Corresponding author: Ranjeny Thomas,  
26

27 email: ranjeny.thomas@uq.edu.au  
28

29 Telephone: +61734436960  
30

31 Fax: +61734436966  
32  
33  
34  
35

36 Short title: Trajectory of intensive treat-to-target DMARDs in RA  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

Objectives: Studies of early rheumatoid arthritis (RA) cohorts have analysed treatment response and prognostic factors at fixed time points. However, in treat-to-target protocols, therapeutic decision-making is dynamic, and responsive to disease activity over time. To determine when a minimal residual disease response target should be expected, our primary objective was to identify the time-dependent therapeutic response to combination disease modifying anti-rheumatic drugs (DMARDs) for 12 months. Our secondary objective determined factors affecting this response trajectory. Design: Observational cohort. Setting: Treat-to-target early RA clinic in Australian tertiary referral hospital. Participants: We enrolled consecutive patients attending an early arthritis clinic with symptom duration less than 12 months, who were diagnosed with RA for the first time between 2004 and 2008. One hundred and one met these eligibility criteria and data were available at baseline through 12 months. Interventions: Intensive DMARDs according to a treat-to-target protocol. Primary and secondary outcome measures: We measured disease activity scores (DAS) at each visit, then analysed therapeutic response and associated factors in a time-dependent fashion over 12 months. Results: The median DAS4vESR of 4.46 at baseline decreased 12 weeks later by 24%, while the proportion with  $DAS4v \leq 2.6$  increased ( $p < 0.01$ ). DAS4v continued to decrease over 52 weeks. DAS4v reduction of at least -0.45 at 4 weeks was predictive of DAS4v at 28 and 52 weeks. Female gender, [current smoking](#), [primary education](#) -and an interaction between baseline weight and CRP negatively impacted DAS4v reduction over 4 and 52 weeks. Time-varying effects of blood pressure, neutrophils, ESR and CRP also significantly influenced DAS4v over 52 weeks. Conclusions: Time-dependent data suggest that the largest reduction of DAS4v to combination DMARDs occurs in the

1  
2  
3  
4  
5  
6  
7 first month of therapy, and this predicts subsequent response. [Variables known to](#)  
8 [impact long-term treatment response in RA also impacted early DAS4v response to](#)  
9 [combination DMARDs.](#)~~The data suggest the need for a controlled trial of treatment~~  
10 ~~change within 1 month, in combination DMARD non responding patients.~~

## 11 Article Summary

### 12 Article focus

- 13 • Best-practice early RA treatment aims to achieve a target response. In clinic  
14 settings of many countries, first-line therapies are DMARDs, including  
15 combination DMARDs
- 16 • We followed an observational cohort for 12 months in a treat-to-target early RA  
17 clinic to identify the time-dependent therapeutic response to combination  
18 DMARDs for 12 months and factors affecting this response trajectory

### 19 Key messages

- 20 • After initiation of combination DMARDs, the largest reduction in disease  
21 activity score occurred in the first month, and its magnitude predicted  
22 subsequent response
- 23 • Disease activity score over 12 months was influenced by female gender and  
24 current smoking, [education level](#) and an interactive effect of weight and either  
25 CRP or ESR
- 26 • ~~The data suggest a need for a controlled trial of treatment change within 1~~  
27 ~~month, in clinical response to combination DMARDs non responding~~  
28 ~~patients~~ [may be more rapid than previously appreciated, and treatment response](#)  
29 [in the first month may have prognostic significance](#)
- 30 • [These hypotheses require further testing in other cohorts.](#)

## Strengths and Limitations

### Strengths

- Monthly observation allowed precise determination of time-dependent therapeutic response and demonstrated an unexpectedly rapid response to combination DMARDs
- Standardised combination DMARD treat-to-target protocol
- Real-life clinical setting with dynamic therapeutic decision making

### Limitations

- Observational cohort study limits conclusions that can be drawn regarding causality, without further testing in a randomised controlled trial
- Relatively small cohort derived from a single centre, with treatment regimen determined within Australian prescribing context, [and exclusions due to missing data](#) limits generalisability.
- Number of participants limited by lack of baseline or 12 month follow-up data and may have introduced selection bias
- Due to incomplete radiographic data, factors associated with radiographic outcomes could not be determined

**BACKGROUND:**

Intervention with early combination disease modifying anti-rheumatic drug (DMARD) therapy favourably influences progression of rheumatoid arthritis (RA) independent of treatment in later years, suggesting that there is a “window of opportunity” in which the disease process can be altered [1, 2]. Moreover, a good response at 6 months to tight disease control using methotrexate predicted outcome after 5 years of treatment in participants in the CAMERA study [3]. The severity of disease varies in RA patients. In those with aggressive disease, damage to articular structures occurs early in the disease process: erosions were detected in 12.8% of patients after a median of 8 weeks in one study [4]. Thus, early evidence and determinants of treatment response to a given regimen are critical, in order to channel patients at greatest risk of poor outcome to more intensive induction regimens or more expensive biologic therapies within that window.

Studies of prognostic factors by statistical modelling have analysed disease progression outcomes including erosions, disease activity score (DAS28) and disability index as measured by Health Assessment Questionnaire (HAQ) at fixed time points – usually 6 or 12 months, with the earliest being 3 months – to determine treatment response and associated factors influencing this. Factors associated with poor radiological outcome include smoking, rheumatoid factor (RF) positivity, the presence of anti-citrullinated peptide autoantibodies (ACPA), HLA-DR genotype, low socioeconomic status and bone oedema on magnetic resonance imaging [5-9]. On the other hand, poor outcome measured by HAQ was associated with high baseline disease activity or HAQ, including RF, DAS28 score, tender and swollen joint counts, ESR and CRP [10, 11]. However, in treat-to-target protocols, such as was used in the TICORA trial and which occur in real-

1  
2  
3  
4  
5  
6  
7 life clinic settings, decision-making about dose and drugs is a dynamic process,  
8 responsive to the patient's disease activity over time [12]. In many early arthritis  
9 protocols, including the current study, patients are treated and monitored intensively  
10 during the first 3-6 months, followed by a reduced visit frequency. Longitudinal  
11 analysis of all available data, while modelling the trajectories and drawing inferences on  
12 the significance of various risk factors, provides higher power and better insight into the  
13 dynamic process.  
14  
15  
16  
17  
18  
19  
20

#### 21 22 23 **AIMS:**

24 In the current study, our primary objective was to identify the time-dependent  
25 therapeutic response in an observational study of combination DMARDs for 12 months  
26 in order to determine when a minimal residual disease response target should be  
27 expected. Our secondary objective was to determine factors affecting this response  
28 trajectory. We therefore gathered disease activity data at each treatment visit then  
29 analyzed the disease activity response in a time-dependent fashion. We then determined  
30 factors which influenced this time-dependent response to an intensive DMARD  
31 regimen.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

#### 42 43 **METHODS:**

44 We enrolled consecutive patients attending-referred by general practitioners from a  
45 relatively socio-economically disadvantaged catchment (60% referrals of employed  
46 individuals working in manual industries) to an a-tertiary-referral-early arthritis clinic in  
47 a public teaching hospital. with symptom duration less than 12-months2 years, who  
48  
49  
50  
51  
52 were diagnosed with RA for the first time between 2004 and 2008. Patients were  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 selected for inclusion in the current study if data were available at baseline through 12  
8  
9 months; however data were not required at every time point for inclusion. Two hundred  
10 and six patients were referred with possible RA and ~~One hundred and one~~101 patients  
11 met these eligibility criteria; 49 did not have RA, and ~~however 107~~ 54 patients who met  
12 all other criteria were excluded as data were unavailable at either baseline or 12 months.  
13 Of these, 7 were seen once and diagnosed with RA then treated elsewhere, and the  
14 remainder were reviewed at least once but not at 12 months. All study participants met  
15 the American College of Rheumatology 1987 revised criteria for the classification of  
16 RA [13]. Ethical approval for retrospective data analysis ~~the study~~ was obtained from the  
17 Metro South Human Research Ethics Committee ~~Committee~~.

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Referrals from local general practitioners were triaged within 1 week, and patients were  
29 generally diagnosed within the next 4 weeks. Since full clinical and laboratory  
30 evaluation was available at the first visit to the early arthritis clinic, patients received  
31 combination methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ)  
32 [14], unless contraindicated, immediately after diagnosis and confirmation of active  
33 disease ~~RA~~ by the treating rheumatologist. Treatment was intensified according to a  
34 response-driven step-up algorithm, as previously described [15], with remission as the  
35 target [16, 17]. Briefly, criteria for dose escalation were either >2 swollen joints and  
36 abnormal ESR or CRP, or at least 2 of the following 4 criteria: morning stiffness  
37 >30mins, pain or fatigue visual analogue scale (VAS) >30mm, or >2 tender joints. The  
38 following medications were prescribed at baseline: MTX 10mg/week, folic acid  
39 5mg/week, SSZ 500mg daily increasing by 500mg at weekly intervals to 1000mg twice  
40 daily, HCQ 200mg daily for one week then 400mg daily thereafter. Patients were seen  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7 at 4-weekly intervals and the MTX dose was escalated according to treatment response  
8  
9 at a conservative rate by 5mg at each visit to a maximum of 25mg weekly. If disease  
10  
11 remained active on this combination, SSZ was stopped, MTX reduced to 10mg weekly  
12  
13 and leflunomide started at a dose of 20mg daily. MTX dose was titrated back to 25mg  
14  
15 weekly, and if this combination failed and the Australian Pharmaceutical Benefit  
16  
17 Scheme criteria were met, the patient commenced biologic therapy. Based on these  
18  
19 criteria, 10% of patients in this setting commenced biologics per year. In general, the  
20  
21 use of NSAIDs and oral corticosteroids was minimized, but intra-articular or oral  
22  
23 steroids could be administered at the discretion of the treating physician. Large joints  
24  
25 were injected with 40-80mg DepoMedrol and smaller joints with 1ml (5.7mg)  
26  
27 Celestone. Oral and intra-articular dosage of corticosteroids was recorded monthly.  
28

29  
30  
31 Response to therapy was measured as follows: the 4 variable DAS28ESR (hereafter  
32  
33 referred to as DAS4v) was used as an index of inflammatory control [18], and the  
34  
35 mHAQ as an index of disability [19]. Each index was calculated at each visit: baseline,  
36  
37 and weeks 4, 8, 12, 16, 22, 28, 36, 44 and 52.  
38

39  
40 Demographic details were ascertained by questionnaire and included: age at  
41  
42 presentation, [symptom duration](#), [level of education](#), gender, ~~smoking status~~[current, ex-](#)  
43  
44 [smokers and non-smokers](#) and mHAQ. Patients completed VAS for pain, fatigue and  
45  
46 their global assessment of disease. The 28 tender and swollen joint counts, height, ~~and~~  
47  
48 weight ~~and~~ [blood pressure \(BP\)](#) were recorded by the clinical research nurse. Blood was  
49  
50 collected at baseline for the analysis of ESR, CRP, LFT, FBC, RF and ACPA. [ACPA](#)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

were measured at Queensland Health Pathology using the anti-CCP2 ELISA (Axis-Shield) test, with the cut-off of 6 for a positive test.


Basic statistics were presented by number (%) or mean (SD) or median (IQR), as appropriate. Five imputations for missing data on clinical, biochemical and score data were performed using Bayesian Markov chain Monte Carlo multiple-imputation technique. Of those who met eligibility criteria for study inclusion, not all patients attended for all visits, however the patterns of missingness were random for all the study parameters. The consistency in the distributions of the 5 imputed data was checked for all study parameters. Given the skewed DAS and mHAQ scores, the medians and their 95% confidence intervals (CI) are presented. The changes in these scores over the study period are presented by median and 95% CI, ~~and the~~ Significance levels (p values) are based on the appropriate non-parametric test.

Generalized multivariate linear regression models with Gamma distribution and Identity link were used to identify the statistically significant ( $p \leq 0.10$ ) risk factors and their possible interaction effects on disease activity scores at week 4 of the study. The possible consistency in the effect sizes of the statistically significant risk factors (at week 4) were also assessed on the disease activity scores at week 12 of the study. Combining the 10 longitudinal measurements obtained over one year of the study, the time varying effects of individual risk factors on the disease activity scores were explored using generalized estimating equation (GEE) regression approach with Gamma distribution and identity link function under the assumption of 'unstructured' correlation structure.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

10

For peer review only



**RESULTS:****Time-dependent therapeutic response to combination DMARDs for 12 months**

One hundred and one patients were included in the study [and 54 \(of whom 7 were only seen once\) were excluded due to missing 12 month follow-up data.](#)—The baseline characteristics of ~~the included and excluded~~ patients are shown in Table 1. [Except for a lower systolic BP in excluded subjects, there were no significant differences between included and excluded subjects.](#) All except 4 patients took at least two and up to three of the following DMARDs in combination during the 12 months study: Methotrexate, Sulfasalazine, Hydroxychloroquine and Leflunomide. These 4 patients took Methotrexate monotherapy.

The median disease activity score at baseline was 4.46 for DAS4v (Table 2). Four of the 12 patients with baseline DAS  $\leq 2.6$  ([minimal disease activity](#)) were taking steroids prior to referral. There was a highly significant ( $p < 0.001$ ) DAS reduction of 24% at 28 weeks (Table 2). We also observed a significant increase in the proportion of patients with minimal residual, (DAS28 ~~scores~~  $\leq 2.6$ ) and low disease (DAS28 ~~scores~~  $\leq 3.2$ ) over the treatment period ( $p < 0.01$ ) (Table 2). Consistent with this, the patients' pain scores improved highly significantly by 31% and 56% at the end of 6-month and one-year of treatment respectively. The improvement in mHAQ from baseline to 6 months, but not between 6 and 12 months of treatment, was significant. The average annual change was 0.30 units (Table 2).

Analysis of the change in DAS4v over time showed a progressive reduction over 52 weeks, with the steepest drop between baseline and 4 weeks (Figure 1). The median

(95% CI) of changes in DAS4v scores at 4, 28 and 52 weeks were -0.45 (-0.84, -0.07), -0.86 (-1.30, -0.41), and -1.35 (-1.67, -1.03) respectively ( $p < 0.01$  at week 52). The changing patterns of the distribution of DAS4v scores over time are evident from the density plots in Figure 2. Although a significant shift in the distribution of DAS4v at 4 weeks from baseline is evident from the density plot, the distributions overlap at 4, 28 and 52 weeks.

Analysis of the individual components of the DAS scores over this period demonstrated that patient global score, swollen and tender joint counts all fell most steeply between baseline and 4 weeks (Figure 2). While this was not the case for the fall in either ESR or CRP, similar steep falls in fatigue score, morning stiffness and physician global scores occurred between baseline and 4 weeks. Thus most measures of disease activity fell most rapidly in the first 4 weeks after DMARD initiation. In contrast, ESR fell for 3 months before reaching a plateau, while CRP fell progressively for 6 months.

### **Factors affecting the response trajectory in early RA patients treated with combination DMARDs**

To determine whether the fall in DAS4v at 4 weeks predicted the DAS score at 28 and 52 weeks, we first calculated that the median level of change in DAS4v score at 4 weeks was -0.45. This was clinically discriminatory: at 4 weeks, 52% had no change or an increase in DAS4v while 48% improved from baseline DAS4v. The number and proportion of patients receiving steroids is indicated in Table 3. While baseline steroids impacted the likelihood of improvement at 4 weeks, this was not statistically significant (69% of patients receiving steroids improved and 53% not receiving steroids improved;

odds ratio for improvement with steroids 1.95,  $p=0.12$ ). Patients with reduction in DAS4v ~~score~~ at 4 weeks of at least -0.45 were three times more likely [OR (95% CI): 3.10 (1.2, 8.0)] at 28 weeks and 17 times more likely [OR (95% CI): 17.14 (4.52, 64.94)] at 52 weeks to maintain the same or reduced DAS4v ~~score~~ as achieved after 4 weeks of treatment. Univariate modelling of factors affecting outcome showed that female sex, smoking status and increasing ALT at baseline negatively affected DAS4v at 4 weeks, but these effects became less significant by 12 weeks (Table 4). An interaction between baseline weight and CRP negatively affected DAS at both week 4 and 12. Patients taking steroid did not have a significantly different disease score, and [symptom duration before RA diagnosis](#), anti-CCP ~~and~~ RF titre did not impact 4 week DAS. [The reduction in DAS4v at 4 weeks was significantly greater in patients with tertiary than with primary education.](#)

Combining baseline characteristics and the longitudinal measurements obtained over one year, we explored the time varying effects of individual risk factors on DAS4v in a univariate model. DAS4v over 52 weeks was again influenced by female gender and current smoking, and an interactive effect of weight and either CRP or ESR. Time varying effects of systolic and diastolic blood pressure, neutrophil counts, ESR and CRP also significantly influenced DAS4v observed over 52 weeks (Table 4). [At week 52, the largest reduction in DAS4v was observed in patients with tertiary education \(3.57\), compared with that observed among patients with secondary \(2.56\) or primary education \(1.33\). Symptom duration prior to diagnosis did not significantly influence DAS4v over 52 weeks.](#) Over the course of the study, DAS4v was increased by 0.66 in those patients taking steroids ( $p < 0.01$ ). These data are in keeping with the use of

steroid in this study at the clinician's discretion, to provide additional control for disease activity that was not controlled by the DMARD protocol.

We found that the relationship between mHAQ and DAS4v for the cohort was significantly correlated at baseline, 4 weeks, 28 weeks and 52 weeks ( $p < 0.001$ ), with this correlation becoming progressively tighter over time as DAS and mHAQ fell. Thus, functional outcome after 1 year of early RA treatment is highly dependent on achievement of low disease activity.

#### DISCUSSION:

Our study describes the response of a group of patients with early RA to intensive conventional DMARD therapy in a time-dependent fashion over the first year. Baseline characteristics were in line with previous cohorts of patients with early RA. However, our baseline DAS scores were relatively low, reflecting our rapid triage and clinical and laboratory assessment of early arthritis referrals. ~~Surprisingly, A key finding from the~~ time-dependent analysis of ~~DAS~~ response, ~~is showed~~ that the majority of disease activity measures fall most rapidly in the first 4 weeks after commencing intensive DMARD treatment ~~in this population~~. There was a subsequent slow and progressive reduction in DAS until week 52. ~~This~~ Moreover, the fall in DAS4v at 4 weeks ~~appeared to be clinically meaningful, as it~~ predicted the DAS ~~score~~ at 28 and 52 weeks. This observation suggests that for patients who ~~failed~~ to respond within 4 weeks to combination DMARD treatment, few gains ~~are were~~ made by continuing to apply the same DMARD treat-to-target algorithm for 6-12 months. ~~This was reflected in the~~ ~~similar proportion of patients with minimal or low disease activity between 6 and 12~~

1  
2  
3  
4  
5  
6  
7 [months. By this stage patients had progressed through the combination DMARD](#)  
8 [algorithm, for which the next step would be biologics. However, because their disease](#)  
9 [activity is minimal or low, they failed to qualify for biologics based on Australia's](#)  
10 [Pharmaceutical Benefit Scheme \(PBS\) requirements \(<http://www.medicareaustralia.gov>](#)  
11 [au/provider/pbs/drugs2/rheumatoid.jsp](#)) [20]. On the other hand, [our data suggest the](#)  
12 [hypothesis that](#) continued effort in applying a treat-to-target combination DMARD  
13 algorithm is likely to be effective over the ensuing months in patients who make a  
14 moderate response by week 4. Our data [further](#) suggest that combination DMARDs act  
15 unexpectedly rapidly [in this early RA population](#), as patients' use of steroids did not  
16 influence the reduction in DAS. In support of this conclusion regarding steroids, in a  
17 study of 61 patients with early RA treated according to a similar response-driven step-  
18 up combination DMARD algorithm, Proudman *et al* obtained an almost identical 6  
19 month [remission-minimal disease activity](#) rate (DAS28<2.6 in 29%), despite infrequent  
20 use of corticosteroids [17].

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 The current study has a number of limitations. Firstly, our interpretation that the  
38 magnitude of the fall in DAS4v after 1 month predicts 1 year outcome is limited by the  
39 observational study design. However, the question of whether outcome could be  
40 improved in patients with a minimal treatment response within 1 month could be tested  
41 in a randomised controlled trial comparing switch to biologic therapy with continued  
42 combination DMARDs. Secondly, this is a relatively small cohort derived from a single  
43 centre [with referrals derived from a relatively socio-economically disadvantaged](#)  
44 [catchment](#), with the treatment regimen determined within the Australian prescribing  
45 context. [At the time of recruitment, 1987 ACR criteria were used to diagnose RA.](#)  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7 which would have limited capacity to diagnose less severe patients. The number of  
8  
9 participants was limited by lack of baseline or 12 month follow-up data and this may  
10  
11 have introduced selection bias towards a more compliant group. ~~While these factors~~  
12 ~~may~~The small sample size and number of exclusions due to incomplete data limit  
13  
14 generalisability to other prescribing environments or clinical settings, and further  
15  
16 studies are needed to test the generalisability of our findings. For example it is possible  
17  
18 that those excluded had a different disease trajectory due to differences risk for poor  
19  
20 outcome or differences in adverse events. A sub-analysis of the trajectory excluded  
21  
22 patients was not possible because of the low number of paired baseline and 4 week  
23  
24 DAS4v measurements in this group. On the other hand, there were no differences in the  
25  
26 baseline characteristics of the excluded patients (except systolic BP). Furthermore,  
27  
28 almost all factors associated with 4 week DAS4v response have been previously  
29  
30 demonstrated to affect disease outcome in longer-term and larger studies. The  
31  
32 strengths of this study are that it analyses real-world data, monthly observations allowed  
33  
34 precise determination of time-dependent response, ~~and and were able to demonstrate an~~  
35  
36 ~~unexpectedly rapid response to combination DMARDs.~~ Furthermore, patients received  
37  
38 a standardised combination DMARD treat-to-target protocol, reducing the confounding  
39  
40 effect of treatment decisions based on individual clinician preference.  
41  
42  
43

44 ~~Finally~~ The exploratory nature of the study in a relatively small sample could introduce  
45  
46 false positive associations. Although it possible that the rapid 4 week response to  
47  
48 combination DMARDs represents regression to the mean, the continued good response  
49  
50 of these patients argues against this. Our data also are consistent with recent studies  
51  
52 demonstrating that early good response to combination therapy (in the TEAR and  
53  
54  
55  
56  
57  
58  
59  
60

RAPID 1 trials) is associated with a continued good response [21, 22]. In these studies, rapid response was ascertained 12 weeks after initiation of combination therapy. By regression analysis, we identified female gender, current smoking, education level, ALT and an interaction between weight and CRP as significant determinants of disease activity over 4 and 52 weeks. Females, ~~and~~ current smokers and low levels of education were found in several studies, including those of early RA, to achieve lower reductions in disease activity or remission ~~than men~~ [23-26]. However, no study has previously determined that the impact of these variables may occur within weeks of commencing treatment. The interaction between weight and inflammation in RA is intriguing and has been noted previously in insulin resistant states [27]. In patients with active RA, those with high BMI responded less well to infliximab [28]. We also identified significant time-varying effects of blood pressure, gender, age, weight and inflammatory markers on disease activity. The interaction between disease activity and cardiovascular risk is well documented in RA, including early RA, and traditional cardiovascular risk factors may also impact the activity of inflammatory disease over time [15, 29-31]. However, it is unknown whether control of cardiovascular risk factors can in turn impact inflammatory disease control.

In this study we were limited to analysis of disease and functional score, as radiographic data were not sufficiently complete to allow measurement of structural damage. However, this issue has been addressed by others, where biomarkers such as ACPA antibodies, RF, CRP and cartilage oligomeric matrix protein can add power to predictive models of bone erosion in early RA [32]. In contrast, we found no impact of ACPA or RF on DAS. Our data confirm a strong relationship between disease activity

1  
2  
3  
4  
5  
6  
7 and functional score that appears to strengthen over time, a finding that is supported by  
8 data from the BeST cohort [16]. We would anticipate that functional disability would be  
9 minimized by early treatment with combination DMARDs as shown previously [33,  
10 34].  
11  
12  
13

14  
15  
16  
17 Since they are traditionally thought to be slow acting, previous studies of DMARD  
18 monotherapy in early RA have not analyzed time-dependent data from 4 weeks.  
19 Although it remains possible that a similar response might be observed in some patients  
20 starting DMARD monotherapy, we suggest this rapid response may be a unique feature  
21 of intensive combination DMARDs ([with multiple mechanisms of action](#)) initiation in  
22 early RA, [which is the RA population most responsive to therapeutic intervention](#) [35,  
23 36]. The risks and benefits of intensive DMARD therapy (combinations allowing  
24 switching to achieve tight control) versus monotherapy in early RA deserve further  
25 study, considering inconsistent evidence to support combination DMARD therapy in  
26 RA [36, 37]. The need to identify patients with more aggressive disease prompted one  
27 group to undertake a trial of a stratified treatment plan based on the likelihood of  
28 persistent arthritis, with the aim of minimizing over- and under-treatment in early RA  
29 [38]. Our data suggest [the hypothesis](#) that very early response to an intensive DMARD  
30 strategy that minimizes under-treatment predicts response for the first year.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Data from the ERAN study show that patients with moderate disease activity at 1 year  
47 are unlikely to achieve better control of their disease if the same protocol is continued,  
48 and a good response at 6 months in the CAMERA study predicted outcome at 5 years  
49 [3, 39]. Our data, collected in a cohort of early RA patients with relatively low baseline  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

DAS, likely reflect the trajectory of patients meeting criteria for RA early in disease, and which would be captured in organized clinical settings using the recently-published new classification criteria [40].

Formatted: English (Australia)

## CONCLUSIONS :

With the availability of increasing numbers of treatment options, application of strategies that identify early non-responders to intensive DMARD combinations, has clear implications for treatment stratification within the window of opportunity. Time-dependent data suggest clinical response to combination DMARDs may be more rapid than previously appreciated, and treatment response in the first month may have prognostic significance. Confirmation in other cohorts will be required to determine the generalisability of this notion.

~~Our time dependent data suggest the need for a controlled trial of early treatment change in patients who fail to respond to combination DMARDs in the first month of therapy. Female gender, smoking, over weight and abnormal LFT increase the risk of early poor response.~~

## DATA SHARING, COMPETING INTERESTS AND FUNDING

No additional data are available. The authors declare no competing interests in relation to this article. Supported by NHMRC grants 351439 and 569938. R.T. is supported by Arthritis Queensland and an ARC Future Fellowship.

Formatted: English (Australia)

## REFERENCES

- 1 Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet* 1999;**353**:1568-73.
- 2 Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;**350**:309-18.
- 3 Bakker MF, Jacobs JW, Welsing PM, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. *Ann Rheum Dis* 2011;**70**:1099-103.
- 4 Machold KP, Stamm TA, Eberl GJ, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. *J Rheumatol* 2002;**29**:2278-87.
- 5 Harrison MJ, Tricker KJ, Davies L, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. *J Rheumatol* 2005;**32**:2330-6.
- 6 Manfredsdottir VF, Vikingsdottir T, Jonsson T, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. *Rheumatology (Oxford)* 2006;**45**:734-40.
- 7 Kaltenhauser S, Pierer M, Arnold S, et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. *Rheumatology (Oxford)* 2007;**46**:100-4.

1  
2  
3  
4  
5  
6  
7 8 Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest  
8  
9 predictor of subsequent radiographic progression in early rheumatoid arthritis. Results  
10  
11 from a 2-year randomised controlled trial (CIMESTRA). *Ann Rheum Dis* 2009;**68**:384-  
12  
13 90.

14  
15 9 Sanmarti R, Gomez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic  
16  
17 progression in early rheumatoid arthritis: a two year prospective study after a structured  
18  
19 therapeutic strategy using DMARDs and very low doses of glucocorticoids. *Clin*  
20  
21 *Rheumatol* 2007;**26**:1111-8.

22  
23 10 Combe B, Cantagrel A, Goupille P. Predictive factors of 5-year health assessment  
24  
25 questionnaire disability in early rheumatoid arthritis. *J Rheumatol* 2003;**30**:2344-49.

26  
27 11 Wagner E, Ammer K, Kolarz G, et al. Predicting factors for severity of rheumatoid  
28  
29 arthritis: a prospective multicenter cohort study of 172 patients over 3 years. *Rheumatol*  
30  
31 *Int* 2007;**27**:1041-8.

32  
33 12 Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for  
34  
35 rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.  
36  
37 *Lancet* 2004;**364**:263-9.

38  
39 13 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association  
40  
41 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*  
42  
43 1988;**31**:315-24.

44  
45 14 O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with  
46  
47 methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three  
48  
49 medications. *N Engl J Med* 1996;**334**:1287-91.

1  
2  
3  
4  
5  
6  
7 15 Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial  
8 arterial wall changes in patients with recent-onset rheumatoid arthritis. *Arthritis Res*  
9 *Ther* 2009;**11**:R51.

10  
11  
12 16 van der Kooij SM, Allaart CF, Dijkmans BA, et al. Innovative treatment strategies  
13 for patients with rheumatoid arthritis. *Curr Opin Rheumatol* 2008;**20**:287-94.

14  
15  
16  
17 17 Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy  
18 with conventional disease-modifying antirheumatic drugs can achieve high response  
19 rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-  
20 inflammatory drug use. *Semin Arthritis Rheum* 2007;**37**:99-111.

21  
22  
23  
24 18 Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score  
25 (DAS28) and European League Against Rheumatism response criteria based on C-  
26 reactive protein against disease progression in patients with rheumatoid arthritis, and  
27 comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*  
28 2009;**68**:954-60.

29  
30  
31  
32 19 Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment  
33 Questionnaire (MDHAQ): assessment of advanced activities of daily living and  
34 psychological status in the patient-friendly health assessment questionnaire format.  
35  
36  
37  
38  
39  
40  
41 *Arthritis Rheum* 1999;**42**:2220-30.

42  
43 20 Lu CY, Williams KM, Day RO. Has the use of disease-modifying anti-rheumatic  
44 drugs changed as a consequence of controlled access to high-cost biological agents  
45 through the Pharmaceutical Benefits Scheme? *Intern Med J* 2007;**37**:601-6.

46  
47  
48 21 van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial  
49 change in disease activity score 28 predicts the likelihood of achieving low disease  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. *J Rheumatol* 2012;**39**:1326-33.

22 Curtis JR, McVie T, Mikuls TR, et al. Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial. *J Rheumatol* 2013;**40**:572-8.

23 Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. *Arthritis Res Ther* 2009;**11**:R7.

24 Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. *Ann Rheum Dis* 2011;**70**:469-75.

25 Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? ERAS Study Group. Early Rheumatoid Arthritis Study. *Ann Rheum Dis* 2000;**59**:794-9.

26 Vliet Vlieland TP, Buitenhuis NA, van Zeben D, et al. Sociodemographic factors and the outcome of rheumatoid arthritis in young women. *Ann Rheum Dis* 1994;**53**:803-6.

27 Lopez-Bermejo A, Hernandez-Aguado I, Vera IJ, et al. Sex-specific, independent associations of insulin resistance with erythrocyte sedimentation rate in apparently healthy subjects. *Thromb Haemost* 2007;**97**:240-4.

28 Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. *Arthritis Rheum* 2011;**63**:359-64.

29 Bartoloni E, Alunno A, Luccioli F, et al. Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. *Expert Rev Cardiovasc Ther* 2010;**8**:1309-16.



30 Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in  
recent onset rheumatoid arthritis: a critical role for inflammation. *Arthritis Res Ther*  
2007;**9**:R116.

31 Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced  
glycation end products and of S100 proteins are associated with inflammatory,  
autoantibody, and classical risk markers of joint and vascular damage in rheumatoid  
arthritis. *Arthritis Res Ther* 2009;**11**:R39.

32 Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint  
damage in rheumatoid arthritis. *Ann Rheum Dis* 2005;**64**:196-201.

33 Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced  
radiographic progression with combination disease modifying antirheumatic drugs in  
early rheumatoid arthritis. *J Rheumatol* 2007;**34**:316-21.

34 Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and  
remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted  
radiographic progression in the 5-year extension of the double-blind randomised  
CIMESTRA trial. *Ann Rheum Dis* 2010;**69**:1789-95.

35 Geletka R, St Clair EW. Treatment of early rheumatoid arthritis. *Best Pract Res Clin  
Rheumatol* 2003;**17**:791-809.

36 Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness  
study of oral triple therapy versus etanercept plus methotrexate in early aggressive  
rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.  
*Arthritis Rheum* 2012;**64**:2824-35.

37 Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2010;**69**:964-75.

38 Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. *BMC Musculoskelet Disord* 2009;**10**:71.

39 Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). *Rheumatology (Oxford)* 2011;**50**:926-31.

40 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;**62**:2569-81.

## TABLES:

**Table 1.** Baseline characteristics of the patients

<u>Baseline variable</u>	<u>Value</u>	
<u>Baseline variable</u>	<u>Included patients (n=101)</u>	<u>Excluded patients (n=54)</u>
Female*	60 (59.4%)	<u>44 (81%)</u>
Age <sup>†</sup> , years	54 (12)	<u>48 (15)</u>
<u>Symptom duration, months<sup>§</sup></u>	<u>12 (5, 12)</u>	<u>6 (4, 12)</u>
Smoking		
Current Smokers	26 (25.7%)	<u>8 (15%)</u>
Ex-Smokers	29 (28.7%)	<u>26 (48%)</u>
<u>Education</u>		
<u>Primary</u>		<u>5 (14%)</u>
<u>Secondary</u>		<u>24 (66%)</u>
<u>Tertiary</u>		<u>9 (24%)</u>
Weight <sup>†</sup> , Kg	77.10 (19.68)	<u>80 (24)</u>
SBP <sup>†</sup> , mm Hg	127 (15)	<u>120 (17)**</u>
DBP <sup>†</sup> , mm Hg	73 (10)	<u>70 (10)</u>
RF*	89 (88.1%)	<u>42 (77%)</u>
ACPA*	51 (50.5%)	<u>9 (36%)</u>
ESR <sup>§</sup> , mm/hour	25 (12, 46)	<u>16 (10, 34)</u>
CRP <sup>§</sup> , mg/liter	9.7 (19, 39)	<u>6 (2, 12)</u>
Lymphocytes <sup>†</sup> , x 10 <sup>9</sup> /L	1.94 (0.67)	<u>2.1 (1.3, 2.5)</u>
Neutrophils <sup>†</sup> , x 10 <sup>9</sup> /L	5.12 (2.50)	<u>5 (3, 6.8)</u>
LFT (AST) <sup>§</sup> , U/L	20.50 (16.50, 24.00)	<u>18.5 (17, 23)</u>

LFT (ALT) <sup>§</sup> , U/L	19 (14, 27)	<a href="#">19 (14, 23)</a>
<a href="#">eGFR<sup>§</sup>, mL/min</a>	<a href="#">89 (74, 90)</a>	
<a href="#">Glucose<sup>§</sup>, mmol/L</a>	<a href="#">5.2 (4.9, 5.75)</a>	

\* Values are n (%); † values are the median (SD); § values are the median (IQR). SD = standard deviation; IQR = interquartile range; RF = Rheumatoid Factor; ~~SBP = systolic blood pressure; DBP = diastolic blood pressure;~~ ACPA = anti-citrullinated peptide antibody; ESR = erythrocyte sedimentation ratio; CRP = C reactive protein; LFT = liver function test; AST = aspartate aminotransferase; ALT = alanine aminotransferase; [\\*\\*p=0.002, eGFR = estimated glomerular filtration rate.](#)

**Table 2. Change in median pain VAS scores, DAS and HAQ scores (95% CI) over 1 year**

	Baseline	6 month	1 year	Change at 6 months	p	Change at 1 year	p
Pain Score	55 (48, 62)	37.9 (31.7, 44.1)	24.2 (17.7, 30.6)	-21.9 (-30.8, -13)	<0.001	-27.4 (-35.6, -19.1)	<0.001
DAS4v	4.5 (4.1, 4.8)	3.4 (3.1, 3.7)	3.2 (2.9, 3.4)	-1.3 (-1.8, -0.8)	<0.001	-1.5 (-2, -1.1)	<0.001
mHAQ	0.6 (0.5, 0.8)	0.44(0.3, 0.6)	0.3 (0.2, 0.4)	-0.3 (-0.5, -0.1)	0.003	-0.3 (-0.4, -0.2)	<0.001
Proportion of patients with:							
DAS ≤ 2.6	12 (14.8%)	25 (25%)	29 (29%)				
DAS ≤ 3.2	18 (22%)	48 (48%)	52 (52%)				

**Table 3. Frequency of steroid use over the study**

Treated with:	Study duration (weeks)					
	0 (0)	4	8	12	16	24
Oral Steroid n (%)	16 (15.8)	17 (16.8)	14 (13.9)	11 (10.9)	1 (1)	1 (1)
IA steroid	21 (20.7)	2 (2)	4 (4)	2 (2)	0	0
Any steroid	37 (36.7)	19 (18.8)	18 (17.8)	13 (12.9)	1 (1)	1 (1)
Oral and IA steroid	3 (3)	1 (1)	2 (2)	0	0	0

IA intra-articular

**Table 4. Variables influencing DAS scores at 4 and 12 weeks of study – Univariate regression**

	DAS4v		DAS4v	
	Week 4		Week 12	
	$\beta$	p	$\beta$	p
Female	0.68	0.009	0.46	0.059
Smoking				
Ex-smokers vs non-smokers	-0.55	0.026	-0.17	0.53
Current smokers vs non-smokers	-0.80	0.003	-0.42	0.10
LFT (ALT)	0.03	0.01	0.04	0.63
Weight*CRP	0.002	0.029	0.002	0.02
Oral or IA Steroid	0.11	0.67	0.01	0.98
Anti-CCP > 6	0.0004	0.99	0.67	0.08

Values are regression coefficient ( $\beta$ ) and p-value. Regression co-efficient at each time point for RF = 0. CRP = C reactive protein; LFT = liver function test; ALT = alanine aminotransferase.

**Table 5. Effects of time-varying risk factors individually on DAS28 scores over 1 year of study – Univariate regression**

	DAS4v		
	$\beta$	95% CI	p
Female	0.45	0.09, 0.81	0.014
Age	0.001	-0.13, 0.02	0.82
Smoking:			
Ex-smokers vs non-smokers	-0.27	-0.70, 0.16	0.22
Current smokers vs non-smokers	-0.48	-0.91, -0.06	0.026
SBP	0.10	0.08, 0.20	<0.001
DBP	0.10	0.04, 0.20	0.004
Lymphocyte	0.04	-0.09, 0.17	0.55
Neutrophil	0.16	0.10, 0.22	<0.001
ESR	0.03	0.03, 0.04	<0.001
CRP	0.02	0.01, 0.02	<0.001
LFT-AST	-0.004	-0.01, 0.003	0.25
LFT-ALT	-0.003	-0.009, 0.004	0.44
Weight*CRP	0.002	0.001, 0.003	<0.001
Weight*ESR	0.004	0.003, 0.005	<0.001
Oral or IA steroid	0.66	0.34, 0.99	P<0.01
Anti-CCP > 6	0.001	-0.001, 0.002	0.36

Regression co-efficient at each time point for RF = 0.



**FIGURES :**

**Figure 1. Distribution of DAS4v over the study period. A:** The median and 95% CI are plotted for each visit over the 52 week study period. **B:** Changes in DAS4v over 4, 28 and 52 weeks are indicated. **C:** The changing distribution in DAS4v in the sample is plotted at baseline, 4, 28 and 52 weeks.





Figure 2. Variation in the disease activity parameters over the study period. The median and 95% CI are plotted for each visit over the 52 week study period for ESR, CRP, tender joint count, swollen joint count, fatigue, morning stiffness, patient global and physician global scores.



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	x
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	x
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	x
Objectives	3	State specific objectives, including any prespecified hypotheses	x
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	x
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	x
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	x
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	x
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	x
Bias	9	Describe any efforts to address potential sources of bias	x
Study size	10	Explain how the study size was arrived at	x
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	x
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	x
		(b) Describe any methods used to examine subgroups and interactions	x
		(c) Explain how missing data were addressed	x
		(d) If applicable, explain how loss to follow-up was addressed	x
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	x
		(b) Give reasons for non-participation at each stage	x
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	x
		(b) Indicate number of participants with missing data for each variable of interest	x
		(c) Summarise follow-up time (eg, average and total amount)	x
Outcome data	15*	Report numbers of outcome events or summary measures over time	x
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	x

		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	x
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	x
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	x
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	x
Generalisability	21	Discuss the generalisability (external validity) of the study results	x
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	x

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.